We are boldly committed to reimagining cancer and blood disorders.
# TABLE OF CONTENTS

Message from the Chairmen ........................................................................................................ 4
Continuing Nursing Education Information .................................................................................. 5
Continuing Medical Education Information .................................................................................... 5
CME/CNE Certificate Information ................................................................................................. 5
Supporter Acknowledgements ........................................................................................................ 7
CME/Disclosure Information ............................................................................................................ 8
Program-at-a-Glance ........................................................................................................................ 18
Meeting Program .............................................................................................................................. 19
  Wednesday, September 9, 2020 .................................................................................................... 19
  Thursday, September 10, 2020 .................................................................................................... 26
  Friday, September 11, 2020 ......................................................................................................... 30
  Saturday, September 12, 2020 .................................................................................................... 34
Program Faculty ................................................................................................................................... 36
General Information ........................................................................................................................... 40
  Virtual Event Venue ....................................................................................................................... 40
  Registration & General Information ............................................................................................... 40
  Resource Center ............................................................................................................................. 40
  Help Desk ....................................................................................................................................... 40
  Exhibition ....................................................................................................................................... 40
Independent Sessions .......................................................................................................................... 41
MESSAGE FROM THE CHAIRMEN

On behalf of the organizing committees, it is our pleasure to welcome you to the eighth annual meeting of the Society of Hematologic Oncology (SOHO). As many of you know, SOHO was established in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies. Since that time, SOHO has grown from a membership base of 400 to nearly 5,000 in 2020. Organized by its founders and world class committees, SOHO is the only society specific to this field.

The theme of this year’s meeting is “Molecular Classification and Precision Therapy.” The program focuses on new advances and practical clinical applications, with special emphasis on novel biological and therapeutic approaches, for patients with hematologic malignancies. In addition, the speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases.

During this 3.5-day event, we will participate in a number of educational sessions including virtual ‘live’ didactic lectures, meet-the-professor sessions, debates, plenary sessions, poster presentations, oral abstract presentations and other virtual interactive exchanges and informal virtual engagement experiences. Topics will include Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, T-Cell Lymphoma, Mantle Cell Lymphoma, Aggressive B-Cell Lymphoma, Indolent B-Cell Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms and Multiple Myeloma.

We hope you will find the meeting productive, informative and enjoyable. We would like to thank all SOHO members, attendees and industry partners whose contributions and participation have been essential to the success of the society.

Sincerely,

Sagar Lonial, MD, FACP | Hagop Kantarjian, MD | Emil J Freireich, MD
Co-Chairmen, Society of Hematologic Oncology Eighth Annual Meeting
CONTINUING NURSING EDUCATION

This nursing continuing professional development activity was approved by Louisiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Activity number: LSNA-100594565-2020.

This CNE activity is being jointly provided by The Society of Hematologic Oncology collaboratively with JWC Covenant, Inc.

**Learning Outcome**

By the end of this conference the learner will know how to identify and apply the latest advances in science, pathophysiology, therapy and appropriate nursing care management for patients with hematologic malignancies, based on current evidence.

**Requirements for Successful Completion**

1. Attendance at one (1) or more sessions.
2. Complete and submit an evaluation form.

Registered attendees can earn up to 23.0 contact hours of continuing nursing education, including 12.0 pharmacotherapeutic contact hours, depending on sessions attended, at the Society of Hematologic Oncology 2020 Annual Meeting.

In order to claim your Contact Hours & Certificate, you will need to go online and complete the Verification and Evaluation Form. Once this form is submitted you will receive your certificate via email. Please be sure to check your junk and/or SPAM mail.

You can access the Evaluation Form either one of the following two ways:

1. Scan the QR code, or;
2. Enter the following url address into your web browser:

   https://www.surveymonkey.com/r/SOHO2020

If you have any questions regarding CNE, please feel free to call Belinda Melder at 281-364-7387 ext 201. The link will be active until Monday, October 19, 2020.

CONTINUING MEDICAL EDUCATION

**Educational Objectives**

After participating in the activity, the participant should be able to:

1. Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of hematologic malignancies (knowledge, competence, performance).
2. Debate the benefits of maintenance therapies in patients with hematologic malignancies and integrate key findings into clinical practice to improve patient care (knowledge, competence, performance).
3. Describe the clinical and molecular facets of biology, pathogenesis, diagnostic approaches and therapeutic modalities available for various hematologic disorders (knowledge, competence).
4. Apply emerging therapies and novel treatment strategies for patients with hematologic malignancies and evaluate the practical utility of novel agents based on data from recent clinical studies to improve outcomes (knowledge, competence, performance, patient outcomes).
5. Differentiate the evolving therapeutic strategies for first-line, second-line, third-line, and salvage treatment of hematologic malignancies and apply these strategies into practice (knowledge, competence, performance).

**Target Audience**

This program is directed towards Physicians, RNs, PAs, PharmDs, Fellows and Students interested in Hematology Oncology, Medical Oncology and Internal Medicine.

**Educational Methods**

Lectures, Case Studies, Panel Discussions, Poster Session, Poster Presentations, Interactive Small Groups, Question-and-Answer Sessions.

**Evaluation**

A course evaluation form will provide participants with the opportunity to comment on the value of the program content...
to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of The University of Texas MD Anderson Cancer Center and the Society of Hematologic Oncology. The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates
To obtain a CME certificate awarding AMA PRA Category 1 Credit™, physicians must submit a completed evaluation questionnaire and a CME Verification Form. MD/DO’s will receive a certificate awarding AMA PRA Category 1 Credit™. All other healthcare professionals will receive a certificate of participation indicating the number of AMA PRA Category 1 Credit™ approved for this activity.

The CME Verification and Evaluation link will be accessible until Monday, October 19, 2020. To submit the CME Verification and Evaluation forms after this date, please contact the Office of CME at 713-792-5357.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audiotaping, and videotaping are prohibited.

In order to claim AMA PRA Category 1 Credits™, record your attendance, and/or evaluate the conference, please follow the QR code or link below:

Please be sure to check your junk and/or SPAM mail.

You can access the Verification and Evaluation Form either one of the following two ways:

1. Scan the QR code, or,

2. Enter the following url address into your web browser: (case sensitive)

   https://bit.ly/2QnGher

   Certificates will not be available after October 19, 2020.

If you have any questions, please contact Harolyn Hardin in CME/Conference Management, MD Anderson Cancer Center at 713-745-0133 or hhardin@mdanderson.org.
SUPPORTER ACKNOWLEDGEMENTS

SUPPORTERS
The conference organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical and nursing education by providing educational grants or donations in support of this symposium:

Platinum Supporters
• Incyte Corporation

Silver Supporters
• AbbVie
• AstraZeneca
• Bristol-Myers Squibb
• Genentech
• GlaxoSmithKline

Bronze Supporters
• Astellas
• Dova Pharmaceuticals
• Jazz Pharmaceuticals, Inc
• Pfizer Oncology
• Seattle Genetics, Inc.

Supporter
• Novartis Oncology

EXHIBITORS
The conference committee wishes to express appreciation to the following companies:

Platinum Exhibitors
• Amgen
• AstraZeneca
• Bristol-Myers Squibb

Gold Exhibitors
• AbbVie
• GlaxoSmithKline
• Incyte Corp.

Silver Exhibitors
• Astellas Pharma
• Bio Ascend
• Janssen Biotech, Inc.
• Jazz Pharmaceuticals

Bronze Exhibitors
• Acceleron Pharma
• Adaptive Biotechnologies
• Agios Pharmaceuticals
• BTG International
• Daiichi Sankyo
• Dova Pharmaceuticals
• Foundation Medicine
• Genentech
• Genmab
• Invivoscribe

Exhibitor
• MD Anderson Cancer Center
• Rigel Pharmaceuticals

Pharmacyclicas an Abbvie Company and Janssen
The University of Texas MD Anderson Cancer Center Disclosure Policy for Program Chair(s), Planning Committee Members, Teachers, or Authors and CME Activity Reviewers

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair(s), planning committee member, faculty/teacher/author, or CME activity reviewer relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact the Department of CME/Conference Management at (713) 792-5357.

**DISCLOSURE INFORMATION**

Faculty / Program Planning Committee Members / CME Activity Reviewers

Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or device to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

### FACULTY: COMMERCIAL INTEREST

<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Grant/Research Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nazha Aziz, MD</td>
<td>Paid Consultant: Abbvie, Daiichi Sankyo; Speaker’s Bureau: Incyte, Novartis; Advisory Committee/Review Panel/Board Membership: MEI</td>
</tr>
<tr>
<td>Uma Borate, MD, MS*</td>
<td>Paid Consultant: Genentech, Daiichi Sankyo, Takeda, Pfizer, Novartis, Jazz; Advisory Committee/Review Panel/Board Membership: Genentech, Daiichi Sankyo, Takeda, Pfizer, Novartis, Jazz</td>
</tr>
<tr>
<td>Prithviraj Bose, MD*</td>
<td>Grant/Research Support: Incyte, Celgene (BMS), C1 BioPharma, Constellation, Kartos, Astellas, Pfizer, NS Pharma, Promedior, Blueprint; Paid Consultant: Incyte; Honoraria: Incyte, Celgene (BMS), C1 BioPharma, Kartos</td>
</tr>
<tr>
<td>Renier J. Brentjens, MD, PhD</td>
<td>Grant/Research Support: Juno Therapeutics; Paid Consultant: Gracell Therapeutics; Advisory Committee/Review Panel/Board Membership: Juno</td>
</tr>
<tr>
<td>Jennifer R. Brown, MD, PhD</td>
<td>Grant/Research Support: Gilead, Loxo, Sun, Verastem; Paid Consultant: AbbVie, AstraZeneca, AstraZeneca, Beigene, Catapult, Dynamo Therapeutics, Juno/Celgene, MEI Pharma, Nextcea, Novartis, Octapharma, Pfizer, Verastem; Advisory Committee/Review Panel/Board Membership: Invectys (safety monitoring committee)</td>
</tr>
<tr>
<td>Elizabeth Budde, MD, PhD</td>
<td>Grant/Research Support: Mustang Therapeutics, Merck, Amgen, AstraZeneca; Paid Consultant: Gilead, Roche</td>
</tr>
<tr>
<td>Jonathon B. Cohen, MD, MS*</td>
<td>Grant/Research Support: AstraZeneca, BMS, Takeda, Genentech, BiolInvent, LAM, Beigene; Paid Consultant: AstraZeneca, Loxo, Cellectar, Gilead, Adicet Bio, Aptitude Health</td>
</tr>
<tr>
<td>Jorge Cortés, MD*</td>
<td>Grant/Research Support: Pfizer, Novartis, Takeda, Sun Pharma; Paid Consultant: Pfizer, Novartis, Takeda</td>
</tr>
<tr>
<td>Nick Cross, MA, PhD, FRCPATH*</td>
<td>Grant/Research Support: Novartis; Honoraria: Novartis, Incyte</td>
</tr>
<tr>
<td>Sandeep S. Dave, MD, MS</td>
<td>Stocks or stock options, excluding diversified mutual funds: Data Driven Bioscience, Inc</td>
</tr>
<tr>
<td>Stéphane De Botton, MD</td>
<td>Grant/Research Support: Agios; Paid Consultant: Agios, Celgene (BMS); Speaker’s Bureau: Celgene (BMS); Honoraria: Celgene (BMS); Advisory Committee/Review Panel/Board Membership: Celgene (BMS)</td>
</tr>
<tr>
<td>Marcos de Lima, MD*</td>
<td>Grant/Research Support: Lentigen; Advisory Committee/Review Panel/Board Membership: Celgene, Pfizer, Kadmon</td>
</tr>
<tr>
<td>Michael W. Deininger, MD, PhD*</td>
<td>Grant/Research Support: Blueprint, Novartis, Incyte, SPARC, LLS, Pfizer; Paid Consultant: Blueprint, Fusion Pharma, Novartis, Sangamo; Advisory Committee/Review Panel/Board Membership: Blueprint, Takeda, Medscape, Incyte, Sangamo</td>
</tr>
</tbody>
</table>

(continued on p. 9)
DISCLOSURES

Courtney D. DiNardo, MD, MSCE*: Grant/Research Support: Celgene; Paid Consultant: AbbVie, Agios, Celgene, Daiichi Sankyo, Jazz; Honoraria: Notable Labs; Stocks or stock options, excluding diversified mutual funds: Notable Labs

John DiPersio, MD, PhD: Grant/Research Support: Amgen; Paid Consultant: Amgen; Honoraria: BioLineRx, Wugen; Advisory Committee/Review Panel/Board Membership: Cellworks Group, Inc., RiverVest Venture Partners; Stocks or stock options, excluding diversified mutual funds: Magenta Therapeutics, WUGEN

Angela Dispenzieri, MD: Grant/Research Support: Takeda, Pfizer, Prothena, Celgene, Alnylam, and Janssen; Advisory Committee/Review Panel/Board Membership: Alnylam, Intellia, Janssen

Alessandra Femaioli, MD: Grant/Research Support: Celgene, Beigene, Acerta

Christopher R Flowers, MD, MS*: Grant/Research Support: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical; Paid Consultant: Abbvie, Bayer, Beigene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmachemicals; Advisory Committee/Review Panel/Board Membership: Spectrum

Nathan H. Fowler, MD: Grant/Research Support: Roche, Celgene, Gilead; Advisory Committee/Review Panel/Board Membership: Roche, Celgene, Gilead

Guillermo García-Manero, MD: Grant/Research Support: Amgen, Novartis, AbbVie, BMS, Astex, Onconova, H3Bio, Merck; Paid Consultant: Astex, BMS, Helsinn

Morie A. Gertz, MD: Paid Consultant: Karyopharm

Larisa Geskin, MD: Grant/Research Support: Kyowa Kirin; Paid Consultant: Helsinn, Malinckrodt; Speaker's Bureau: Helsinn; Honoraria: Helsinn, Medscape, UpToDate; Advisory Committee/Review Panel/Board Membership: Helsinn, Malinckrodt

Paolo Ghia, MD, PhD*: Grant/Research Support: AbbVie, Gilead, Janssen, Novartis, Sunesis; Honoraria: AbbVie, Acceleron/AstraZeneca, ArQule, Adaptive, Dynamo, Janssen, MEI, Sunesis

Sergio Giralt, MD*: Grant/Research Support: Amgen, Accellinium, Celgene, Johnson & Johnson, Miltenyi, Takeda; Omeros; Advisory Committee/Review Panel/Board Membership: Amgen, Accellinium, Celgene, Johnson & Johnson, Janssen, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma

Michael Hallek, MD*: Speaker's Bureau: Roche, Gilead, Mundipharma; Paid Consultant: AbbVie, Celgene, Pharmacyscics, AbbVie; Honoraria: Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyscics, AbbVie

Alex F. Herrera, MD*: Grant/Research Support: Bristol-Myers Squibb, Genentech, Immune Design, AstraZeneca, Merck, Seattle Genetics, Kite Pharma, Gilead Sciences; Paid Consultant: Bristol-Myers Squibb, Genentech, Merck, Adaptive Biotechnologies, Kite Pharma, Gilead

Jens Hillengass, MD*: Advisory Committee/Review Panel/Board Membership: Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Oncotracker

Gabriela Hobbs, MD: Grant/Research Support: Bayer, Merck, Incyte; Advisory Committee/Review Panel/Board Membership: SAB-Celgene/BMS, Incyte, Novartis, Agios, Jazz

Steven M. Horowitz, MD, PhD*: Grant/Research Support: ADC Therapeutics, Celgene Seattle Genetics, Verastem Oncology, Aileron Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Forty Seven, Portola Pharmaceuticals, Trillium Therapeutics; Honoraria: ADC Therapeutics, Astex, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics TakeDea, Verastem Oncology

Tim P. Hughes, MD, MBBS: Grant/Research Support: Novartis; Honoraria: Novartis, BMS; Advisory Committee/Review Panel/Board Membership: Novartis, BMS, Fusion Pharma, Spare Pharma

Martin Hutchings, MD, PhD*: Grant/Research Support: Takeda, Roche, Genmab, Celgene, Janssen; Advisory Committee/Review Panel/Board Membership: Takeda, Roche, Genmab

Elias Jabbour, MD*: Grant/Research Support: Amgen, Pfizer,

(...continued on p. 10)
DISCLOSURES

Takeda, Adaptive, Novartis, Spectrum, AbbVie, BMS

Nitin Jain, MD*: Grant/Research Support: PCYC, AbbVie, Genentech, BMS, AZD; Paid Consultant: PCYC, AbbVie, Genentech, AZD; Honoraria: PCYC, AbbVie, Genentech, BMS, AZD

Andrzej Jakubowiak, MD, PhD*: Grant/Research Support: Amgen; Paid Consultant: AbbVie, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm; Honoraria: AbbVie, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm; Advisory Committee/Review Panel/Board Membership: AbbVie, Amgen, Celgene/BMS, GSK, Janssen, Karyopharm

Rami S. Komrokji, MD*: Paid Consultant: Agios, AbbVie, Celgene, Incyte, Pfizer, Jazz; Speaker’s Bureau: Agios, AbbVie, Jazz

Marina Y. Konopleva, MD, PhD*: Grant/Research Support: AbbVie, Genentech, Roche, AstraZeneca, Ablynx; Agios, Forty Seven, Lilly, Cellectis, Stemline; Paid Consultant: AbbVie, Genentech, Roche, Amgen, Forty Seven; Honoraria: Stemline, Kisoji; Advisory Committee/Review Panel/Board Membership: Roche; Stocks or stock options, excluding diversified mutual funds: Reata Pharm

Andrea A. Lane, MD, PhD*: Grant/Research Support: AbbVie, Stemline Therapeutics; Paid Consultant: N-of-One/Qiagen

Steven Le Gouill, MD, PhD: Paid Consultant: Roche, Janssen, Gilead Kite, Abbvie, Jazz, Servier, Loxo, Celgene, Daiichi Sankyo

Suzanne Lentzsch, MD, PhD*: Grant/Research Support: Sanofi, Karyopharm; Advisory Committee/Review Panel/Board Membership: Sorrento, Cellularity, Hanseen; Stocks or stock options, excluding diversified mutual funds: Caelum Biosciences

Coleman Lindsay, MD, PhD: Grant/Research Support: Jazz Pharmaceuticals; Paid Consultant: Jazz Pharmaceuticals, Takeda Pharmaceuticals

Brea C. Lipe, MD*: Grant/Research Support: Amgen, BMS, Cellectar, Karyopharm, Celgene; Advisory Committee/Review Panel/Board Membership: Amgen, Janssen, Celgene

Aaron Logan, MD, PhD*: Grant/Research Support: Kite, Jazz, Pharmacycicles, Kadmon, Amphivena; Advisory Committee/Review Panel/Board Membership: Amgen, Agios

Sagar Lonial, MD, FACP*: Grant/Research Support: Janssen, BMS, Takeda; Paid Consultant: Janssen, Celgene, Takeda, Novartis, BMS, Amgen, GSK, AbbVie

Selina M. Lugir, MD*: Grant/Research Support: Biosight, Celgene, Hoffman La Roche, Kura, Onconova; Honoraria: Acceleron, Agios, Daiichi-Sankyo, BMS, Jazz

Robert Marcus, MA, FRCP, FRCPath: Paid Consultant: Roche, Genentech; Honoraria: Roche, Genentech

Thomas G. Martin, MD*: Grant/Research Support: Sanofi, Amgen, Janssen, Seattle Genetics; Paid Consultant: GSK

Maria-Victoria Mateos, MD, PhD*: Honoraria: Janssen, Celgene, Takeda, Amgen, Adaptive, Abbvie, GSK, Roche, Seattle Genetics; Advisory Committee/Review Panel/Board Membership: Janssen, Celgene, Takeda, Amgen, Adaptive, Abbvie, GSK, Roche, Seattle Genetics

Richard Maziarz, MD*: Paid Consultant: Kite Therapeutics, Celgene J uno; Honoraria: Pace Biopharma, Omeros; Advisory Committee/Review Panel/Board Membership: Novartis, Athersys Therapeutics, Incyte

Laura C. Michaelis, MD*: Grant/Research Support: Jazz Pharmaceuticals; Advisory Committee/Review Panel/Board Membership: Jazz Pharmaceuticals

Carol Moreno, MD, PhD*: Grant/Research Support: AbbVie, Janssen, BMS, Janssen, Sunesis, AstraZeneca; Speaker’s Bureau: Janssen

Lori Muffly, MD: Grant/Research Support: Adaptive, Astellas, Servier; Paid Consultant: Amgen, Pfizer, Kite

Nikhil C. Munshi, MD*: Paid Consultant: Adaptive, Astellas, Amgen, BMS, Takeda, Oncopep; Advisory Committee/Review Panel/Board Membership: Janssen, Takeda, Adaptive Biotechnology, Karyopharm; Stocks or stock options, excluding diversified mutual funds: Oncopep

Loretta Nastoupil, MD*: Grant/Research Support: Celgene, Genentech, Janssen, Karus, Lam, Merck, Novartis, TG Therapeutics; Honoraria: Bayer, Celgene, Genentech, Gilead/KITE, Janssen, Novartis, TG Therapeutics

Satva S. Neelapu, MD*: Grant/Research Support: Kite/Gilead, Merck, BMS, Cellectis, Poseida, Karus, Acerta, AlloGene, Unum Therapeutics, Precision Biosciences; Advisory Committee/Review Panel/Board Membership: (...continued on p. 11)
Kite/Gilead, Merck, BMS/Celgene, Novartis, Unum Therapeutics, Pfizer, Precision Biosciences, Cell Medica, Allogene, Incyte, Legend Biotech; Other Relevant Financial or Material Interests (please specify): Royalty form Takeda (phone app)

Ajay K. Nooka, MD, MPH, FACP: Grant/Research Support: Takeda, Janssen, Amgen; Advisory Committee/Review Panel/Board Membership: Amgen, Janssen, Takeda, Celgene, Sanofi, BMS, GSK, Oncoproteins, Karyopham

Ariela Noy, MD: Grant/Research Support: Pharmacycics, Raphael Pharma; Honoraria: Medscape, Pharmacycics; Advisory Committee/Review Panel/Board Membership: Janssen, Morphosys

Robert Z. Orłowski, MD, PhD*: Grant/Research Support: BioTheoryX; Advisory Committee/Review Panel/Board Membership: Amgen, Bristol-Myers Squibb, Celgene, EcoR1 Capital, LLC, Future Therapeutics, Genzyme, GSK Biologicals, Ionis Pharm., Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Sanofi-Aventis, Servier, Takeda Pharmaceuticals, North America, Inc.

Eric Padron, MD*: Grant/Research Support: Incyte, Kura, Humanigen; Speaker’s Bureau: Novartis

Jae Park, MD*: Paid Consultant: Intella, Servier, Amgen, Takeda, Pfizer, AstraZeneca, Kite Pharma, Novartis; Advisory Committee/Review Panel/Board Membership: Artiva

Daniel O. Persky, MD*: Paid Consultant: Cellectar, Kymera; Advisory Committee/Review Panel/Board Membership: Morphosys, Debiopharm

Uwe Platzbecker, MD: Honoraria: Novartis, AbbVie, Celgene, Janssen, Takeda; Advisory Committee/Review Panel/Board Membership: Novartis, AbbVie, Celgene, Janssen, Takeda

Daniel Pollyea, MD, MS*: Grant/Research Support: AbbVie, Pfizer; Honoraria: Daichi Sankyo, Takeda; Advisory Committee/Review Panel/Board Membership: Janssen, Forty-Seven, AbbVie, Celgene, Amgen

Jerald P. Radich, MD: Paid Consultant: Genentech, Cepheid, BMS, Takeda, Novartis

Raajit K. Rampal, MD, PhD: Grant/Research Support: Stemline, Incyte, Constellation; Paid Consultant: Constellation, Celgene, Incyte, Promedior, CTI, Jazz, Blueprint

Delphine Rea, MD, PhD*: Honoraria: Novartis, Pfizer, Incyte; Advisory Committee/Review Panel/Board Membership: Novartis, Pfizer, Incyte

Peter Riedell, MD*: Grant/Research Support: Kite/Gilead, Novartis, Celgene/BMS; Paid Consultant: Novartis; Speaker’s Bureau: Bayer, Kite/Gilead; Advisory Committee/Review Panel/Board Membership: Celgene/BMS, Bayer, Novartis

David A. Salmon, MD*: Grant/Research Support: Celgene, Jazz; Speaker’s Bureau: AbbVie, Agios, Incyte, Novartis; Advisory Committee/Review Panel/Board Membership: Agios, Celyad, Intella

Valeria Santini, MD*: Honoraria: Celgene, Janssen, Novartis; Advisory Committee/Review Panel/Board Membership: Takeda, Novartis, Pfizer, Menarini, Amgen

Keny Savage, MD*: Grant/Research Support: Roche (Institutional); Paid Consultant: Servier; Honoraria: Merck, Seattle Genetics, Bristol-Myers Squibb, AbbVie, AstraZeneca

Kjeld Schmiegelow, MD: Honoraria: Jazz Pharmaceuticals, Servier; Advisory Committee/Review Panel/Board Membership: Jazz Pharmaceuticals, Servier

Laurie Sehn, MD*: Grant/Research Support: Roche/Genentech; Paid Consultant: Amgen, Apobimetrix, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopham, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem; Honoraria: Amgen, Apobimetrix, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopham, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem

John Seymour, MBBS, FRACP, PhD: Grant/Research Support: AbbVie, Celgene, Janssen, Roche; Paid Consultant: AbbVie, Celgene, Roche; Speaker’s Bureau: AbbVie, Celgene, Roche, Honoraria: AbbVie, Celgene, Janssen, Roche; Advisory Committee/Review Panel/Board Membership: AbbVie, Acerta, Celgene, Janssen, Roche

Elizabeth J. Shpall, MD*: Paid Consultant: Novartis, Magenta, Adaptimmune, Celgene, Partner Therapeutics; Honoraria: Magenta, Novartis, Partner Therapeutics; Advisory Committee/Review Panel/Board Membership: Novartis, Magenta, Adaptimmune, Celgene, Partner Therapeutics

Catherine Smith, MD*: Grant/Research Support: Revolution

(...continued on p. 12)
Medicines, Abbvie, Fuji Film; Paid Consultant: Astellas Pharma, Daichi Sanyko

**Sonali M. Smith, MD, FASCO***: Grant/Research Support: FortySeven, Genentech, Celgene, TG Therapeutics, Pharmacycics, Acerta, Portola, Novartis, Karyopharm; Paid Consultant: Karyopharm, Genentech, TG Therapeutics, Celgene; Other Relevant Financial or Material Interests (please specify): Paid internal educational lecture for Karyopharm MSL’s

**Simona Soverini, PhD**: Paid Consultant: Incyte Biosciences

**David J. Straus, MD***: Honoraria: Takeda

**Marion Subklewe, MD**: Grant/Research Support: Amgen, Gilead, Miltenyi, Morphosys, Roche, Seattle Genetics; Speaker’s Bureau: Amgen, Celgene, Gilead, Pfizer; Advisory Committee/Review Panel/Board Membership: Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, Seattle Genetics

**Koichi Takahashi, MD**: Grant/Research Support: Onconova; Paid Consultant: GS; Advisory Committee/Review Panel/Board Membership: Symbio Pharmaceuticals

**Alessandra Tedeschi, MD**: Speaker’s Bureau: Janssen spa, AbbVie; Advisory Committee/Review Panel/Board Membership: Janssen spa, AbbVie, AstraZeneca, Biogene

**Sheeba K. Thomas, MD***: Grant/Research Support: BMS/Celgene, X4 Pharma; Advisory Committee/Review Panel/Board Membership: Ascentage

**Philip A. Thompson, MB, BS***: Grant/Research Support: AbbVie, Pharmacycics, Genentech, AstraZeneca, Janssen spa; Advisory Committee/Review Panel/Board Membership: Ascentage

**Geoffrey L. Uy, MD***: Honoraria: AstraZeneca, Celgene, Amgen, AstraZeneca; Speaker’s Bureau: Janssen; Honoraria: Janssen

**Srdan Verstovsek, MD, PhD***: Grant/Research Support: Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI Biopharma, Genentech, Blueprint Medicines, Novartis, Siena Oncology, Pharma Essentia, AstaZeneca, Ital Pharma, Protagonist Therapeutics; Paid Consultant: Constellation, Pragmatist, Siena, Incyte, Novartis, Celgene

**Peter M. Voorhees, MD***: Grant/Research Support: Celgene, Novartis, Oncopeptides; Advisory Committee/Review Panel/Board Membership: Celgene, Janssen

**Vitae Paresh Vyas, MRCPath, FRCP, FRCPath***: Grant/Research Support: BMS, GSK, CD47 Inc.; Honoraria: BMS, Pfizer, Daiichi Sankyo, JAZ, Astellas; Advisory Committee/Review Panel/Board Membership: Auron Therapeutics; Stocks or stock options excluding diversified mutual funds: Oxstem Oncology

**Michael L. Wang, MD***: Grant/Research Support: Pharmacycics; Janssen; AstraZeneca; Kite; Juno; Celgene; Loxo Oncology; VelosBio; Verastem; Molecular Templates; Oncotemal; InnoCare; BioInvent; Paid Consultant: Pharmacycics; Celgene; Janssen; AstraZeneca; Pulse Biosciences; Guidepoint Global; Kite; Juno; Celgene; Loxo Oncology; BioInvent; InnoCare; Oncotemal; DTRM Biopharma; Honoraria: Pharmacycics; Janssen; AstraZeneca; Targeted Oncology; Dava Oncology

**William Werda, MD, PhD**: Grant/Research Support: GSK/Novartis, Abbvie, Genentech, Pharmacycics, Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE, Sunesis, Miragen, Oncotemal Therapeutics, Cyclacel, Loxo Oncology, Janssen, Xencor

**Amer Zeidan, MBBS***: Grant/Research Support: Celgene/BMS, AbbVie, Astex, Pfizer, Medimmune/Astra-Zeneca, Boehringer-Ingeheim, Trovagene, Incyte, Takeda, Novartis, Aprea, ADC Therapeutics; Paid Consultant: AbbVie, Otsuka, Pfizer, Celgene/BMS, JAZ, Incyte, Agios, Boehringer-Ingeheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme; Honoraria: AbbVie, Otsuka, Pfizer, Celgene/BMS, JAZ, Incyte, Agios, Boehringer-Ingeheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme; Other Relevant Financial or Material Interests (please specify): Travel support: Pfizer, Novartis, Celgene, Trovagene

**Pier Luigi Zinzani, MD, PhD***: Speaker’s Bureau: Celtrion, MSD, BMS, Takeda, Janssen, Verastem; Honoraria: MSD, BMS, Celtrion, Takeda, Janssen, Verastem

**Emanuele Zucca, MD***: Grant/Research Support: AstraZeneca, Celgene, Janssen, Merck, Roche; Advisory Committee/Review Panel/Board Membership: Celgene, Roche, Celtrion Healthcare, Kite/Gilead; Other Relevant Financial or Material Interests (please specify): Roche, AbbVie (Travel Grant)

(...) continued on p. 13)
DISCLOSURES

PLANNING COMMITTEE MEMBERS: COMMERCIAL INTEREST

Michael Andreeff, MD, PhD: Grant/Research Support: Daiichi-Sankyo, United Therapeutics, ONO Pharmaceuticals, Karyopharm, Amgen, AstraZeneca; Paid Consultant: Daiichi-Sankyo, Jazz Pharma, Celgene, Amgen, AstraZeneca; Stocks/stock options, excluding diversified mutual funds: Reata, Aptose, Eutropics, SentiBio, Oncocytecs, Oncolyze

Steve M. Ansell, MD, PhD: Grant/Research Support: BMS, Seattle Genetics, Affimed, Trillium, Regeneron, Pfizer

Michael R. Bishop, MD: Grant/Research Support: Novartis, Kite-Gilead; Paid Consultant: Celier Therapeutics, Novartis, Kite-Gilead; Speaker’s Bureau: Celgene, Agios; Advisory Committee/Review Panel/Board Membership: Optum Health

Renier J. Brentjens, MD, PhD: Grant/Research Support: Juno Therapeutics; Advisory Committee/Review Panel/Board Membership: Juno Therapeutics/Gracell

Jorge Cortés, MD: Grant/Research Support: BMS, Novartis, Takeda, Sun Pharma; Paid Consultant: BMS, Novartis, Pfizer, Takeda

Nick Cross, MA, PhD, FRCPath: Grant/Research Support: Novartis; Honoraria: Novartis, Incyte, Sangamo, Thermo-Fisher; Advisory Committee/Review Panel/Board Membership: Novartis, Incyte, Sangamo

Florencia Cymbalista, MD, PhD: Honoraria: Roche, Janssen, AbbVie, AstraZeneca

Daniel J. DeAngelo, MD, PhD: Grant/Research Support: GlycoMimetics, AbbVie, Novartis, Blueprint; Paid Consultant: Amgen, Autolus, Blueprint, Celgene, Incyte, J. Jazz, Novartis, Pfizer, Shire, Takeda

Michael Deininger, MD, PhD: Paid Consultant: Blueprint, Pfizer, Fusion Pharma, Ascentage Pharma, TRM, Adelphi, Novartis, Sangamo; Advisory Committee/Review Panel/Board Membership: Blueprint, Pfizer, Takeda, Ascentage Pharma, Incyte; Other Relevant Financial or Material Interests (please specify): Novartis-Case Author

Meletios A. Dimopoulos, MD: Grant/Research Support: Amgen, Janssen, Sanofi Oncology, Takeda, Genesis Pharma; Paid Consultant: Amgen, Janssen, Takeda, BMS, Celgene; Honoraria: Amgen, Janssen, Takeda, Celgene


Angela Dispenzieri, MD: Paid Consultant: Takeda, Pfizer, Prothena, Celgene, Alnylam, Janssen; Advisory Committee/Review Panel/Board Membership: Alnylam, Intellia

Hervé Dombret, MD: Paid Consultant: Chugai, Sanofi Aventis; Honoraria: BMS, Celgene, Genzyme, Novartis; Advisory Committee/Review Panel/Board Membership: BMS, Celgene, Genzyme

Barbara Eichhorst, MD: Grant/Research Support: Janssen, Gilead, Roche, AbbVie, Beigene; Paid Consultant: Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQule, AstraZeneca, Oxford Biomedica (UK); Speaker’s Bureau: Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, Adaptive Biotechnologies; Advisory Committee/Review Panel/Board Membership: Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQuile, AstraZeneca, Oxford Biomedica (UK)

Pierre Fenaux, MD: Grant/Research Support: Celgene, Roche, AbbVie, Janssen; Honoraria: Celgene, Roche, AbbVie, Janssen

Alessandra Ferrajoli, MD: Grant/Research Support: Celgene, BeiGene, Acerta; Advisory Committee/Review Panel/Board Membership: Grants of Cancer Care - AstraZeneca

Nathan Fowler, MD: Grant/Research Support: Roche, Celgene, Gilead; Advisory Committee/Review Panel/Board Membership: Roche, Celgene, Gilead

Guillermo Garcia-Manero, MD: Grant/Research Support: AmphiVena, Helsinn, Celgene, Novartis, AbbVie, BMS, Astex, Onconova, H3Bio, Merck; Paid Consultant: Astex, BMS, Helsinn

Paolo Ghia, MD: Grant/Research Support: AbbVie, Gilead, Janssen, Novartis, Sunesis; Paid Consultant: AbbVie, Acer/AltrastZeneca, Adaptive, BeiGene, Dynomia, Janssen, Juno, Sunesis, Toler, Verastem

Irene Ghobrial, MD: Paid Consultant: Amgen, Celgene, BMS, Sanofi, Janssen, Takeda

Sergio Giralt, MD: Grant/Research Support: Amgen, Actinium,

(...continued on p. 14)
DISCLOSURES

Celgene, Johnson & Johnson, Mitlenyi, Takeda, Omeros; Advisory Committee/Review Panel/Board Membership: Amgen, Actinium, Celgene, Johnson & Johnson, Janssen, Jazz Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma

Lucy Godley, MD, PhD: Advisory Committee/Review Panel/Board Membership: Invitae, Inc.

Andre Goy, MD, MS: Grant/Research Support: Acerta, Celgene, Constellation, Genentech, Hoffman La Roche, Infinity, Janssen, Karyopharm, KITE/GILEAD; Paid Consultant: Kite/Gilead, Acerta, Xcenda; Honoria: Kite/Gilead, Janssen, Celgene, Acerta, AstraZeneca, Xcenda; Advisory Committee/Review Panel/Board Membership: Acerta, AstraZeneca, Janssen, Kite/Gilead, Xcenda

Dieter Hoelzer, MD, PhD: Paid Consultant: Servier, Menarini; Honoraria: Amgen, Shire, Jazz Pharma, Medac; Advisory Committee/Review Panel/Board Membership: JUNO-DSMB, IEO-SAB

Steven M. Horwitz, MD: Grant/Research Support: ADC Therapeutics, Aileron, BeGene, Celgene, Corvus, Daiichi Sankyo, Forty Seven, Inc., GlaxoSmithKline, Kyowa Hakko Kirin, Merck & Co., Inc., Millennium/Takeda, Miragen, Portola, Seattle Genetics, Tillium, Verastem; Paid Consultant: Astex, Celgene, Kura Oncology, Kyowa Kirin, Myeloid Therapeutics, Portola, Seattle Genetics, Takeda, Verastem

Tim P. Hughes, MD, MBBS: Grant/Research Support: Novartis; Honoraria: Novartis, BMS; Advisory Committee/Review Panel/Board Membership: Novartis, BMS, Fusion Pharma, Spare Pharma

Elias Jabbour, MD: Grant/Research Support: Pfizer, Takeda, AbbVie, Spectrum; Paid Consultant: Pfizer, Takeda, AbbVie, Spectrum

Sundar Jagannath, MD: Paid Consultant: AbbVie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Karyopharm Therapeutics, Merck & Co.

Joseph Jurcic, MD: Grant/Research Support: AbbVie, Actinium Pharmaceuticals, Arog Pharmaceuticals, Astellas, Celgene, Daiichi Sankyo, Forma Therapeutics, Genentech, Kura Oncology, PTC Therapeutics, Syros Pharmaceuticals; Paid Consultant: AbbVie, Cellgene, Daiichi Sankyo, Genentech, Boston Biomedical; Advisory Committee/Review Panel/Board Membership: Actinium Pharmaceuticals, Novartis

Tapan Kadia, MD: Grant/Research Support: BMS, Celgene, Pfizer, Amgen, Jazz; Paid Consultant: Novartis, Agios, AbbVie, Jazz, Pfizer, Genentech

Hagop Kantarjian, MD: Grant/Research Support: AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer; Honoria: AbbVie, Agios, Amgen, Immunogen, Pfizer, Takeda; Advisory Committee/Review Panel/Board Membership: Actinium

Partow Kebriaei, MD: Grant/Research Support: Amgen; Paid Consultant: Jazz, Kite, Pfizer

Eva Kimby, MD, PhD: Paid Consultant: Roche, Gilead, AbbVie, Janssen; Advisory Committee/Review Panel/Board Membership: Genmab, Bayer

Thomas Kipps, MD, PhD: Grant/Research Support: AbbVie, Pharmacycics, Oncternal, Genentech-Roche; Paid Consultant: AbbVie, Pharmacycics, Celgene, Genentech-Roche, Gilead; Speaker’s Bureau: AbbVie, Pharmacycics, Janssen, Verastem; Honoria: Janssen, Gilead, AbbVie, Pharmacycics, Verastem

Rami S. Komrokji, MD: Paid Consultant: AbbVie, Agios, Celgene, DSI, Incyte, Pfizer, Jazz Pharma; Speaker’s Bureau: Jazz, Agios, AbbVie

Marina Konopleva, MD: Grant/Research Support: AbbVie, Genentech, Roche, AstraZeneca, Ablynx, Amgen, Forty Seven, Lilly Cellectis, Stemline; Paid Consultant: AbbVie, Genentech, Roche, Amgen, Forty Seven; Honoria: Stemline, Kisoji; Advisory Committee/Review Panel/Board Membership: Roche (steering committee); Ownership Interest (e.g., stocks, stock options and other ownership interests, excluding diversified mutual funds): Reata Pham (shareholder)


Mary Jo Lechowicz, MD: Paid Consultant: Kyowa Kirin, Inc., ADC Therapeutics

Suzanne Lentzsch, MD, PhD: Grant/Research Support: Sanofi, Karyopharm; Paid Consultant: Caelum Biosciences; Advisory Committee/Review Panel/Board Membership: DSMB Sorrento, Ad Board BMS, Takeda, Sanofi; Stocks or stock options, excluding diversified mutual funds: Caelum Biosciences

(...continued on p. 15)
DISCLOSURES

Georg Lenz, MD, PhD: Grant/Research Support: Morphosys, AstraZeneca, Janssen, Celgene, Roche, Agios, Gilead, Verastem, Aquinox, Bayer; Paid Consultant: AstraZeneca, Janssen, Celgene, Roche, BMS, Bayer, Novartis; Advisory Committee/Review Panel/Board Membership: AstraZeneca, Janssen, Celgene, Roche, BMS, Bayer, Morphosys, Novartis

Jeffrey M. Lipton, PhD, MD, FRCPC: Grant/Research Support: Novartis, BMS, Takeda, Pfizer, Janssen; Honoraria: Pfizer; Advisory Committee/Review Panel/Board Membership: Takeda, Pfizer

Alan List, MD: Grant/Research Support: Celgene; Paid Consultant: CBMG, Aileron, Forty Seven Inc, Orseni; Advisory Committee/Review Panel/Board Membership: Amphivena, Celgene, LAM, Rigel

Sagar Lonial, MD: Grant/Research Support: Celgene, Janssen, Takeda; Paid Consultant: Amgen, Takeda, AbbVie, Janssen, Celgene, Novartis, GSK, Juno, Merck


Selina M. Luger, MD: Grant/Research Support: Onconova, Seattle Genetics, Kura, Celgene, Hoff man La Roche, Ariad, Biosight; Honoraria: Pfizer, Agios, Daiichi Sankyo

Robert Marc us, MA, FRC, FRCPath: Paid Consultant: Gilead; Speaker's Bureau: Roche, Genentech; Honoraria: Roche, Genentech; Advisory Committee/Review Panel/Board Membership: Gilead

Thomas G. Martin, MD: Grant/Research Support: Sanofi, Amgen, Seattle Genetics, Janssen; Paid Consultant: Roche, Juno Therapeutics

Laura C. Michaels, MD: Grant/Research Support: Jazz Pharmaceuticals

Emili Montserrat, MD: Paid Consultant: Menarini; Advisory Committee/Review Panel/Board Membership: Pharmacys, Janssen, AstraZeneca

Carol Moreno, MD, PhD: Grant/Research Support: AbbVie, Janssen; Paid Consultant: AbbVie, Janssen, Sunesis, AstraZeneca; Speaker's Bureau: Janssen

Franck Morschhauser, MD, PhD: Honoraria: Roche, Janssen; Advisory Committee/Review Panel/Board Membership: Roche, Celgene, Gilead, Epizyme, Verastem, Servier

Alison J. Moskowitz, MD: Grant/Research Support: Seattle Genetics, BMS, Merck, Incyte, Kyowa Hakko Kirin, Miragen; Honoraria: Seattle Genetics, BMS, Takeda, ADCTherapeutics, Miragen, Cell Medica, Erytech Pharma

Lori Muffly, MD: Grant/Research Support: Baxalta, Adaptive Biotechnologies, Astellas; Paid Consultant: Kite, Pfizer, Gilead

Ay K. Nooka, MD, MPH, FACP: Grant/Research Support: Takeda, Janssen, Amgen; Advisory Committee/Review Panel/Board Membership: Amgen, Janssen, Takeda, Celgene, Sanofi, BMS, GSK, Oncopeptides, Karyopham

Susan M. O'Brien, MD: Grant/Research Support: Kite, Regeneron, Acerta, Gilead, Pharmacys, TG Therapeutics, Pfizer, Sunesis; Paid Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Inc., AbbVie, Alexion, Verastem, Eisai, Juno Therapeutics, Gilead, Pharmacys, TG Therapeutics, Pfizer, Sunesis

Ryuzo Ohno, MD: Paid Consultant: Nippon Shinyaku, Co., LTD.

Robert Orlowski, MD: Grant/Research Support: Amgen, BioTherTX, Spectrum Pharma; Advisory Committee/Review Panel/Board Membership: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Sanofi-Aventis, Takeda

Eric Padron, MD: Grant/Research Support: Incyte, Kura, Humanigen; Speaker's Bureau: Novartis

Prof. Francesco Passamonti, MD: Speaker's Bureau: Novartis; Honoraria: Novartis, Celgene, Roche, Gilead, CTI Biopharma; Advisory Committee/Review Panel/Board Membership: Novartis, Celgene, Gilead, CTI Biopharma

Uwe Platzbecker, MD: Grant/Research Support: Amgen, Celgene, Janssen, Bergen Bio, Novartis; Honoraria: Celgene, Janssen, Novartis

Ching-Hon Pui, MD: Honoraria: Amgen, Erytech pharma, Servier; Advisory Committee/Review Panel/Board Membership: Adaptive Biotechnologies, Inc

John Radford, MD: Grant/Research Support: Takeda; Paid Consultant: Takeda, BMS, Novartis, ADC Therapeutics

(...continued on p. 16)
DISCLOSURES

Speaker’s Bureau: Takeda, Seattle Genetics, Novartis; Honoraria: Takeda; Advisory Committee/Review Panel/Board Membership: Takeda, Seattle Genetics, Novartis; Stocks or stock options, excluding diversified mutual funds: GSK

Jerald P. Radich, MD: Paid Consultant: Amgen, Cephalon, Novartis, BMS, Takeda

Farhad Ravandi, MD: Grant/Research Support: Amgen, BMS, Xencor, Organix, Macrogenics; Paid Consultant: Amgen, BMS, Astellas, AbbVie, Celgene, AstraZeneca; Honoraria: Amgen, Astellas, Celgene, BMS, AstraZeneca, AbbVie, Novartis

Delphine Rea, MD, PhD: Honoraria: Incyte, Novartis, Pfizer; Advisory Committee/Review Panel/Board Membership: Incyte, Novartis, Pfizer

Josep-Maria Ribera, MD, PhD: Grant/Research Support: Amgen, Pfizer, Novartis, Celgene, Ariad; Paid Consultant: Amgen, Novartis, Ariad; Advisory Committee/Review Panel/Board Membership: Amgen, Pfizer, Ariad, Novartis

Simon Rule, MD: Grant/Research Support: Janssen; Paid Consultant: Janssen, Sunesis, Roche, AstraZeneca; Speaker’s Bureau: Janssen; Honoraria: Janssen, Sunesis, Roche, AstraZeneca; Advisory Committee/Review Panel/Board Membership: Janssen

Giuseppe Saglio, MD: Paid Consultant: Novartis, BMS, ARIAD, Pfizer, Incyte; Speaker’s Bureau: Novartis, BMS, ARIAD, Pfizer, Incyte

Valeria Santini, MD: Honoraria: Celgene, Janssen, Novartis; Advisory Committee/Review Panel/Board Membership: Amgen, Astex, Menarini, Pfizer, Takeda, Celgene, Novartis

Ken Savage, MD: Grant/Research Support: (institutional) Roche; Paid Consultant: Seattle Genetics, Servier; Honoraria: Merck, Seattle Genetics, BMS, Abbvie, AstraZeneca

Richard Schlenk, MD, PhD: Grant/Research Support: Pfizer, Daiichi Sankyo, AstraZeneca, PhamarMar, Roche; Speaker’s Bureau: Pfizer, Novartis, Daiichi Sankyo; Advisory Committee/Review Panel/Board Membership: Daiichi Sankyo, Novartis

Laurie Sehn, MD, MPH: Grant/Research Support: Roche/Genentech; Paid Consultant: Roche/Genentech, AbbVie, Amgen, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem; Honoraria: Roche/Genentech, AbbVie, Amgen, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem

Bijal D. Shah, MD: Grant/Research Support: Incyte, Jazz, Kite/Gilead; Paid Consultant: Kite/Gilead, Novartis, Celgene/Juno, Spectrum/Acrotech, Adaptive, AstraZeneca, Pharmacyclics

Elizabeth Shpall, MD: Paid Consultant: Novartis, Magenta, Adaptimmune, Celgene, Partner Therapeutics; Honoraria: Novartis, Partner Therapeutics; Advisory Committee/Review Panel/Board Membership: Novartis, Magenta, Adaptimmune, Celgene, Partner Therapeutics

Simona Soverini, PhD: Grant/Research Support: Incyte Biosciences; Paid Consultant: Novartis, BMS, Incyte Biosciences

Wendy Stock, MD: Grant/Research Support: Astellas, Pfizer, Amgen, Agios, Daiichi, Kite, Jazz

Richard M. Stone, MD: Grant/Research Support: AbbVie, Arog, Novartis; Paid Consultant: AbbVie, Arog, Celgene, Daiichi-Sankyo, Novartis; Advisory Committee/Review Panel/Board Membership: Agios, Amgen, DSMB Argenx, Astellas, BioLineRx, Celgene, Takeda, Trovagene

Moshe Talpaz, MD: Grant/Research Support: Abbvie, Novartis, CTI Biopharma, Constellation, Celgene, NS Pharma; Advisory Committee/Review Panel/Board Membership: Celgene, CTI Biopharma

Evangelos Terpos, MD, PhD: Grant/Research Support: Amgen, Takeda, Janssen; Paid Consultant: Janssen; Honoraria: Amgen, Takeda, Janssen, Celgene, Medison, Genesis; Advisory Committee/Review Panel/Board Membership: Celgene

Srdan Verstovsek, MD, PhD: Grant/Research Support: Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp., Genentech, Blueprint Medicines Corp., Novartis, Sera Oncology, Pharma Essentia, AstraZeneca, ItaI Pharma, Protagonist Therapeutics; Paid Consultant: Constellation, Pragmatist, Sera, Incyte, Novartis, Celgene

Julie Vose, MD: Grant/Research Support: Acerta/AstraZeneca, Celgene, Incyte Corp., Kite Pharma, Novartis, Seattle Genetics, Inc.; Paid Consultant: AbbVie, Epizyme, Legend Pharmaceuticals, Janssen/Pharmacyclics, Kite

(...continued on p. 17)
DISCLOSURES

Pharma, Acerta/AstraZeneca, Verastem, Miltenyi Biotech, Inc., Loxo Oncology, Allogene, Wugene, Celgene; Honora-
ria: AbbVie, Epizyme, Legend Pharmaceuticals, Janssen/-Pharmaceuticals, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca,
Verastem, Miltenyi Biotech, Inc., Loxo Oncology, Allogene, Wugene, Celgene

John S. Welch, MD, PhD: Grant/Research Support: Janssen
Pharmaceuticals, Notable Labs; Paid Consultant: Rigel
Pharmaceuticals, ArcherDx

William Wierda, MD, PhD: Grant/Research Support: GSK/
Novartis, Abbvie, Genentech, Pharmacyclics LLC, Acerta
Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma,
Sunesis, Miragen, OncTernal Therapeutics, Inc., Cyclacel,
Loxo Oncology, Inc., Janssen, Xencor

Thomas E. Witzig, MD: Grant/Research Support: Celgene,
Acerta, Spectrum; Honoraaria: Karyopharm Therapeutics,
Immune Design; Advisory Committee/Review Panel/Board
Membership: Celgene, MorphoSys, AbbVie, Incyte, Spectrum

Anas Younes, MD: Grant/Research Support: Janssen, Curis,
Merck, BMS, Syndax; Paid Consultant: Biopath, Xynomics,
Epizyme, Roche, Celgene, HCM; Honoraaria: Janssen,
AbbVie, Merck, Curis, Epizyme, Roche, Takeda

Pier Luigi Zinzani, MD, PhD: Speaker's Bureau: Janssen,
Roche, Gilead, Kirin, BMS, Merck; Honoraaria: Janssen,
Roche, Gilead, Kirin, BMS, Merck; Advisory Committee/
Review Panel/Board Membership: Janssen, Roche, Gilead,
Kirin, BMS, Merck

Faculty, Program Planning Committee Members and CME
Activity Reviewers/Approvers have indicated NO financial
interests, arrangements or affiliations with the manufacturer
of any product or devices to be discussed, or who may
financially support this CME activity. An asterisk (*) indi-
cates that the faculty’s presentation will include discussion
of investigational or off-label uses of a product.

FACULTY

Edwin Pascal Alyea, MD*        Jennifer McNeer, MD, MS*
Rosana Córdova, MD              Uday Popat, MD*
Juan José Del Moral, MD          Ayalew Tefferi, MD*
Ghada ELGohary, MD               Francisco Vega, MD Ph

Joseph Jacinth, MD              Virginia Volpe, MD
Shengling Ma, MD                 Joachim Yahalom, MD, FACR

PLANNING COMMITTEE MEMBERS

Elia Anaisie, MD                  Maro Ohanian, DO
Janet M. Cesak, MBA, BS          Uday R. Popat, MD
Andres Chang, MD, PhD            Mark Roschewski, MD
Elhu Estey, MD                    Shirley A. Roy, MPH
Emil J. Freireich, MD            Ayalew Tefferi, MD
Anthony M. Hunter MD             Millie Toth, MS, RN, AOCN

CME ACTIVITY REVIEWERS

Teresa Moon Calderon, MD        Huifang Lu, MD, PhD
Larry C. Driver, MD              

CME ACTIVITY REVIEWERS/APPROVERS

Diane Bodurka, MD

(...cont. from p. 16)
# Program-at-a-Glance

<table>
<thead>
<tr>
<th>Wednesday 10 September</th>
<th>Thursday 11 September</th>
<th>Friday 11 September</th>
<th>Saturday 12 September</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Welcome/Introduction</strong></td>
<td><strong>SESSION I: ALL</strong></td>
<td><strong>SESSION V: MM</strong></td>
<td><strong>SESSION VII: HL</strong></td>
</tr>
<tr>
<td><strong>SESSION II: MDS</strong></td>
<td><strong>SESSION IV: MPN</strong></td>
<td><strong>SESSION VIII: T-CELL LYMPHOMA</strong></td>
<td><strong>SESSION XIII: CML</strong></td>
</tr>
<tr>
<td><strong>SESSION III: AML</strong></td>
<td><strong>SESSION VI: CML</strong></td>
<td><strong>SESSION IX: INDOLENT B-CELL LYMPHOMA</strong></td>
<td><strong>SESSION XIV: NEXT QUESTIONS</strong></td>
</tr>
<tr>
<td><strong>SESSION II: MDS</strong></td>
<td><strong>SESSION VII: MM</strong></td>
<td><strong>SESSION X: AGGRESSIVE B-CELL LYMPHOMA</strong></td>
<td><strong>Closing Remarks</strong></td>
</tr>
<tr>
<td><strong>SESSION III: AML</strong></td>
<td><strong>SESSION VIII: T-CELL LYMPHOMA</strong></td>
<td><strong>SESSION XI: MANTLE CELL LYMPHOMA</strong></td>
<td><strong>SESSION XII: CELLULAR THERAPY</strong></td>
</tr>
<tr>
<td><strong>SESSION III: MPN</strong></td>
<td><strong>SESSION XII: CML</strong></td>
<td><strong>SESSION XIII: CML</strong></td>
<td><strong>SESSION XIV: NEXT QUESTIONS</strong></td>
</tr>
<tr>
<td><strong>SESSION III: MPN</strong></td>
<td><strong>SESSION XIV: NEXT QUESTIONS</strong></td>
<td><strong>SESSION XV: CAR-T</strong></td>
<td><strong>Closing Remarks</strong></td>
</tr>
<tr>
<td><strong>SESSION III: MPN</strong></td>
<td><strong>SESSION XV: CAR-T</strong></td>
<td><strong>SESSION XVI: CAR-T</strong></td>
<td><strong>Closing Remarks</strong></td>
</tr>
</tbody>
</table>

*See page 40 for additional details regarding independent sessions. Industry Expert Sessions and Independent Satellite Symposia are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting.*

**Legend:** ABCL: aggressive B-cell lymphoma; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia; CT: cellular therapy; ET: essential thrombocythemia; HL: Hodgkin lymphoma; IBCL: indolent B-cell lymphoma; IES: industry expert session; ISS: independent satellite symposium; MCL: mantle cell lymphoma; MDS: myelodysplastic syndromes; MPN: myeloproliferative neoplasms; MTP: meet the professor; PV: polycythemia vera; TCL: T-cell lymphoma

**Timing:** Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).
MEETING PROGRAM

Wednesday, September 9, 2020

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td><strong>MTP Session I: AML</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Vitae Vyas</td>
<td></td>
<td><a href="https://soho.click/mtp1">https://soho.click/mtp1</a></td>
</tr>
<tr>
<td></td>
<td>IDH Inhibition</td>
<td>Stéphane De Botton, MD</td>
<td>Institut de Cancérologie Gustave Roussy Paris, France</td>
</tr>
<tr>
<td></td>
<td>FLT3 Inhibition</td>
<td>Catherine Smith, MD</td>
<td>University of California San Francisco San Francisco, California, USA</td>
</tr>
<tr>
<td></td>
<td>Approaches to Understand Mechanisms of Resistance and Response to AML Therapies Using Single Cell Approaches</td>
<td>Vitae Paresh Vyas, MRCPath, FRCP, FRCP</td>
<td>Weatherall Institute of Molecular Medicine Oxford, United Kingdom</td>
</tr>
<tr>
<td>6:45 AM</td>
<td><strong>MTP Session II: ALL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Ching-Hon Pui</td>
<td></td>
<td><a href="https://soho.click/mtp2">https://soho.click/mtp2</a></td>
</tr>
<tr>
<td></td>
<td>How The COG Is Approaching The High Risk Patient With ALL - Incorporation Of Immunotherapy Into Frontline Treatment</td>
<td>Jennifer McNeer, MD, MS</td>
<td>The University of Chicago Medicine Chicago, Illinois, USA</td>
</tr>
<tr>
<td></td>
<td>Management of Toxicity in AYAs with ALL</td>
<td>Kjeld Schmiegelow, MD</td>
<td>Copenhagen University Hospital Copenhagen, Denmark</td>
</tr>
<tr>
<td></td>
<td>How to Use an MRD Result in AYAs Receiving Pediatric Regimens?</td>
<td>Aaron Logan, MD, PhD</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, USA</td>
</tr>
<tr>
<td>6:45 AM</td>
<td><strong>MTP Session III: NHL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Nathan Fowler</td>
<td></td>
<td><a href="https://soho.click/mtp3">https://soho.click/mtp3</a></td>
</tr>
<tr>
<td></td>
<td>Role of Transplant in Lymphoma</td>
<td>Sonali M. Smith, MD, FASCO</td>
<td>The University of Chicago Medicine Chicago, Illinois, USA</td>
</tr>
<tr>
<td></td>
<td>CNS Lymphoma</td>
<td>Christopher R Flowers, MD, MS</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td></td>
<td>What is the Optimal Frontline Regimen in FL</td>
<td>Nathan H. Fowler, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>6:45 AM</td>
<td><strong>MTP Session IV: NHL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Laurie Sehn</td>
<td></td>
<td><a href="https://soho.click/mtp4">https://soho.click/mtp4</a></td>
</tr>
<tr>
<td></td>
<td>Hodgkin Lymphoma</td>
<td>Pier Luigi Zinzani, MD</td>
<td>University of Bologna Bologna, Italy</td>
</tr>
<tr>
<td></td>
<td>Double Hit Lymphoma</td>
<td>Laurie Sehn, MD, MPH</td>
<td>BC Cancer Vancouver, Canada</td>
</tr>
<tr>
<td></td>
<td>CAR T-Cell Therapy for Lymphoma</td>
<td>Sattva S. Neelapu, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).

(...continued on p. 20)
### MTP Session V: CML
**Session Chair:** Jerry Radich

<table>
<thead>
<tr>
<th>TIME (UTC)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>Selecting the Right TKI</td>
<td>Jorge Cortés, MD</td>
<td><a href="https://soho.click/mtp5">https://soho.click/mtp5</a> Georgia Cancer Center Augusta, Georgia, USA</td>
</tr>
<tr>
<td></td>
<td>CML Management in Resource Limited Countries</td>
<td>Jerald P. Radich, MD</td>
<td>Fred Hutchinson Cancer Research Center Seattle, Washington, USA</td>
</tr>
<tr>
<td></td>
<td>Is NGS Ready for Clinical Practice: Advantages and Limitations</td>
<td>Simona Soverini, MD</td>
<td>University of Bologna Bologna, Italy</td>
</tr>
</tbody>
</table>

### MTP Session VI: MPN
**Session Chair:** Uday Popat

**CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?**

<table>
<thead>
<tr>
<th>TIME (UTC)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>A Young Woman with Thrombocytosis</td>
<td>Prithviraj Bose, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td></td>
<td>A Young Man with Polycythemia Vera and Fatigue</td>
<td>Gabriela Hobbs, MD</td>
<td>Massachusetts General Hospital Boston, Massachusetts, USA</td>
</tr>
<tr>
<td></td>
<td>A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis</td>
<td>Uday Popat, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
</tbody>
</table>

### MTP Session VII: MDS
**Session Chair:** Koichi Takahashi

<table>
<thead>
<tr>
<th>TIME (UTC)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>Pitfalls in Assessing Response to Treatment in MDS</td>
<td>Uwe Platzbecker, MD</td>
<td>Leipzig University Hospital Leipzig, Germany</td>
</tr>
<tr>
<td></td>
<td>The Spectrum of Clonal Hematopoiesis from CHIP to AML</td>
<td>Koichi Takahashi, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td></td>
<td>Challenges in Diagnosis and Risk Stratification of MDS</td>
<td>Aziz Nazha, MD</td>
<td>Cleveland Clinic Cleveland, Ohio, USA</td>
</tr>
</tbody>
</table>

### MTP Session VIII: MM
**Session Chair:** Thomas Martin

<table>
<thead>
<tr>
<th>TIME (UTC)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>Latest Treatment Approaches in AL Amyloidosis</td>
<td>Suzanne Lentzsch, MD, PhD</td>
<td>Columbia University New York Presbyterian Hospital New York, USA</td>
</tr>
<tr>
<td></td>
<td>Emerging Therapy</td>
<td>Thomas G. Martin, MD</td>
<td>University of California San Francisco San Francisco, California, USA</td>
</tr>
</tbody>
</table>

---

*All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).*

(...continued on p. 21)
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6:45 AM</strong></td>
<td><strong>MTP Session IX: CLL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chair: Emili Montserrat</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BTK and Monoclonal Antibodies</td>
<td>Carol Moreno, MD, PhD</td>
<td>University of Barcelona Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>BTK and CIT</td>
<td>Philip A. Thompson, MB, BS</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td>BTK and BCL2</td>
<td>Nitin Jain, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td><strong>6:45 AM</strong></td>
<td><strong>MTP Session X: CT</strong> (no credit given for this session)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chair: Susan Prockop</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD19 CAR T Cells for Adults</td>
<td>David L. Porter, MD</td>
<td>University of Pennsylvania Philadelphia, Pennsylvania, USA</td>
<td></td>
</tr>
<tr>
<td>EBV CTLs for PTLD - Ready for Prime Time</td>
<td>Susan Prockop, MD</td>
<td>Memorial Sloan-Kettering Cancer Center New York, New York, USA</td>
<td></td>
</tr>
<tr>
<td>Vaccines and Immunotherapy</td>
<td>David E. Avigan, MD</td>
<td>Beth Israel Deaconess Medical Center Dana-Farber/Harvard Cancer Center Boston, Massachusetts, USA</td>
<td></td>
</tr>
<tr>
<td><strong>7:45 AM</strong></td>
<td><strong>Exhibit Hall Experience</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM</strong></td>
<td><strong>MTP Session XI: AML</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chair: Courtney DiNardo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Changing the Treatment Paradigm in AML</td>
<td>Daniel Pollyea, MD, MS</td>
<td>University of Colorado Denver, Colorado, USA</td>
<td></td>
</tr>
<tr>
<td>Targeting the Microenvironment</td>
<td>Geoffrey L. Uy, MD</td>
<td>Washington University School of Medicine St. Louis, Missouri, USA</td>
<td></td>
</tr>
<tr>
<td>Familial AML</td>
<td>Courtney D. DiNardo, MD, MSCE</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM</strong></td>
<td><strong>MTP Session XII: ALL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chair: Elias Jabbour</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>How I Approach the Treatment of T-ALL in Adults in 2020</td>
<td>Nitin Jain, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td>How I Treat the Older Adult with B-ALL</td>
<td>Elias Jabbour, MD</td>
<td>MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td>How I Approach the Patient Who Has MRD Or Relapse After Transplant</td>
<td>Lori Muffy, MD</td>
<td>Stanford University Medical Center Palo Alto, California, USA</td>
<td></td>
</tr>
</tbody>
</table>

*All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).*
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td><strong>MTP Session XIII: NHL</strong>&lt;br&gt;Session Chair: Loretta Nastoupil</td>
<td>Primary Mediastinal Large Cell Lymphoma&lt;br&gt;Pier Luigi Zinzani, MD</td>
<td><a href="https://soho.click/mtp13">https://soho.click/mtp13</a>&lt;br&gt;University of Bologna&lt;br&gt;Bologna, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of Radiation Therapy in HL&lt;br&gt;Joachim Yahalom, MD, FACR</td>
<td>Memorial Sloan Kettering Cancer Center&lt;br&gt;New York, New York, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemo Free Regimens in Lymphoma&lt;br&gt;Loretta Nastoupil, MD</td>
<td>MD Anderson Cancer Center&lt;br&gt;Houston, Texas, USA</td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>MTP Session XIV: NHL</strong>&lt;br&gt;Session Chair: Ariela Noy</td>
<td>Strategies for Developing Novel Therapies and Aggressive Lymphomas&lt;br&gt;Christopher R. Flowers, MD, MS</td>
<td><a href="https://soho.click/mtp14">https://soho.click/mtp14</a>&lt;br&gt;MD Anderson Cancer Center&lt;br&gt;Houston, Texas, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment of Early Stage DLBCL&lt;br&gt;Daniel O. Persky, MD</td>
<td>University of Arizona Cancer Center&lt;br&gt;Tucson, Arizona, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Burkitt Lymphoma&lt;br&gt;Ariela Noy, MD</td>
<td>Memorial Sloan Kettering Cancer Center&lt;br&gt;New York, New York, USA</td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>MTP Session XV: CML</strong>&lt;br&gt;Session Chair: Jerry Radich</td>
<td>Selecting the Right TKI&lt;br&gt;Jorge Cortés, MD</td>
<td><a href="https://soho.click/mtp15">https://soho.click/mtp15</a>&lt;br&gt;Georgia Cancer Center&lt;br&gt;Augusta, Georgia, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CML Management in Resource Limited Countries&lt;br&gt;Jerald P. Radich, MD</td>
<td>Fred Hutchinson Cancer Research Center&lt;br&gt;Seattle, Washington, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Is NGS Ready for Clinical Practice: Advantages and Limitations&lt;br&gt;Simona Soverini, MD</td>
<td>University of Bologna&lt;br&gt;Bologna, Italy</td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>MTP Session XVI: MPN</strong>&lt;br&gt;Session Chair: Uday Popat</td>
<td>CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?</td>
<td><a href="https://soho.click/mtp16">https://soho.click/mtp16</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Young Woman with Thrombocytosis&lt;br&gt;Prithviraj Bose, MD</td>
<td>MD Anderson Cancer Center&lt;br&gt;Houston, Texas, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Young Man with Polycythemia Vera and Fatigue&lt;br&gt;Gabriela Hobbs, MD</td>
<td>Massachusetts General Hospital&lt;br&gt;Boston, Massachusetts, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis&lt;br&gt;Uday Popat, MD</td>
<td>MD Anderson Cancer Center&lt;br&gt;Houston, Texas, USA</td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).

(...continued on p. 23)
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8:00 AM</strong></td>
<td><strong>MTP Session XVII: MDS</strong></td>
<td>How Do I Treat: Lower Risk MDS</td>
<td>Valeria Santini, MD</td>
</tr>
<tr>
<td></td>
<td>Session Chair: Rami Komrokji</td>
<td>How Do I Treat: Higher Risk MDS</td>
<td>Rami Komrokji, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>How Do I Treat: MDS/MPN</td>
<td>Eric Padron, MD</td>
</tr>
<tr>
<td></td>
<td><strong>MTP Session XVIII: MM</strong></td>
<td>Waldenstroms Macroglobulinemia</td>
<td>Sheeba K. Thomas, MD</td>
</tr>
<tr>
<td></td>
<td>Session Chair: Sheeba Thomas</td>
<td>Bone Diseases and Supportive Care</td>
<td>Jens Hillengass, MD</td>
</tr>
<tr>
<td></td>
<td><strong>MTP Session XIX: CLL</strong></td>
<td>Managing BTK Inhibitor Toxicities</td>
<td>Alessandra Ferrajoli, MD</td>
</tr>
<tr>
<td></td>
<td>Session Chair: Phil Thompson</td>
<td>Managing BCL2 Toxicities</td>
<td>John Seymour, MBBS, FRACP, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Managing Cellular Therapy Toxicities</td>
<td>Jae Park, MD</td>
</tr>
<tr>
<td></td>
<td><strong>MTP Session XX: CT</strong></td>
<td>Point of Care CAR T Cells</td>
<td>Marcos de Lima, MD</td>
</tr>
<tr>
<td></td>
<td>Session Chair: Sergio Giralt</td>
<td>CAR vs Transplant for NHL</td>
<td>Richard Maziarz, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of CAR T Cells in Relapsed Myeloma</td>
<td>Andrzej Jakubowiaik, MD, PhD</td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).

(...continued on p. 24)
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA</strong> (no credit given for this session)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Session Chairs: Dieter Hoelzer and Wendy Stock</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Welcome and Opening Remarks</td>
<td>Sagar Lonial, MD, FACP</td>
<td><a href="https://soho.click/intro">https://soho.click/intro</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>President, Society of Hematologic Oncology</td>
</tr>
<tr>
<td>9:25 AM</td>
<td>In Relapsed B-ALL, How Should We Best Sequence the New Targeted Agents?</td>
<td>Emily Cuman, MD</td>
<td><a href="https://soho.click/all1">https://soho.click/all1</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The University of Cincinnati</td>
</tr>
<tr>
<td>9:43 AM</td>
<td>Mini- Hyper - CVD Combinations for Older Adults: Results of Recent Trials and A Glimpse into the Future</td>
<td>Marlise R. Luskin, MD, MSCE</td>
<td><a href="https://soho.click/all2">https://soho.click/all2</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dana Farber Cancer Institute, Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>10:01 AM</td>
<td>Who Should Receive an Allogeneic Transplant in First Complete Remission?</td>
<td>Josep-Maria Ribera, MD, PhD</td>
<td><a href="https://soho.click/all3">https://soho.click/all3</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Catalan Institute of Oncology, Barcelona, Spain</td>
</tr>
<tr>
<td>10:19 AM</td>
<td>What’s the Latest Innovation in CAR-T Therapy? Fast-Off, Dual Targeting and Other New Tricks</td>
<td>Martin Pule, MB BCH, MRCP</td>
<td><a href="https://soho.click/all4">https://soho.click/all4</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cancer Institute, Univ College London, London, United Kingdom</td>
</tr>
<tr>
<td>10:37 AM</td>
<td>Genomics of Drug Response in ALL: Predicting Response and Concerns for Triggering Relapse</td>
<td>Jun J. Yang, PhD</td>
<td><a href="https://soho.click/all5">https://soho.click/all5</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>St. Jude Children's Research Hospital, Memphis, Tennessee, USA</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>DEBATE: Is Less More? Intensive vs Non-Intensive Approach to Adults with Ph+ ALL</td>
<td>Nicholas Short, MD</td>
<td><a href="https://soho.click/all6">https://soho.click/all6</a></td>
</tr>
<tr>
<td></td>
<td>Intensive Approach</td>
<td></td>
<td>MD Anderson Cancer Center, Houston, Texas, USA</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Non-Intensive Approach</td>
<td>Sabina Chiaretti, MD, PhD</td>
<td><a href="https://soho.click/all7">https://soho.click/all7</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sapienza University, Rome, Italy</td>
</tr>
<tr>
<td>11:31 AM</td>
<td>Oral Abstract</td>
<td>Saleem Eldadah, MD</td>
<td><a href="https://soho.click/all8">https://soho.click/all8</a></td>
</tr>
<tr>
<td></td>
<td>ALL-312: Sixteen Years’ Experience in Treating Adolescents and Young Adult (AYA) with Philadelphia-Negative Acute Lymphoblastic Leukemia (Ph- ALL) with a Modified Pediatric ALL Protocol</td>
<td></td>
<td>Princess Noorah Oncology Center, Ministry of the National Guard Health Affairs, Jeddah, Saudi Arabia</td>
</tr>
</tbody>
</table>

**INDUSTRY EXPERT SESSION IA**

| 11:41 AM | An Acute Myeloid Leukemia Treatment Option for Patients | Hetty Carraway, MD, MBA | [https://soho.click/jes1a](https://soho.click/jes1a) |
| | | | Cleveland Clinic, Cleveland, Ohio, USA |

**INDUSTRY EXPERT SESSION IB**

| 11:41 AM | A CAR T-cell Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma TECARTUS™ (brexucabtagne autoleucel) Prescribing Information | David Rizzieri, MD | [https://soho.click/jes1b](https://soho.click/jes1b) |
| | | | Duke University School of Medicine, Durham, North Carolina, USA |

12:41 PM | Exhibit Hall Experience | | [https://soho.click/exhibits](https://soho.click/exhibits) |

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting.*

(...continued on p. 25)
MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PLENARY SESSION I</strong></td>
<td>Session Chair: Sagar Lonial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:11 PM</td>
<td><strong>Keynote Speaker:</strong> Immunotherapy for T-Cell ALL and T-NHL</td>
<td>John DiPersio, MD, PhD</td>
<td><a href="https://soho.click/plen1">https://soho.click/plen1</a> Washington University St. Louis, Missouri, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Recipient of the SOHO 2020 Distinguished Lecturer Award</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION II: MYELODYSPLASTIC SYNDROMES</strong></td>
<td>Session Chairs: Guillermo Garcia-Manero and Valeria Santini</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:31 PM</td>
<td>New Approaches for Anemia in MDS</td>
<td>Uwe Platzbecker, MD</td>
<td><a href="https://soho.click/mds1">https://soho.click/mds1</a> Leipzig University Hospital Leipzig, Germany</td>
</tr>
<tr>
<td>1:49 PM</td>
<td>Development of Oral HMAS for MDS</td>
<td>Guillermo Garcia-Manero, MD</td>
<td><a href="https://soho.click/mds2">https://soho.click/mds2</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>2:07 PM</td>
<td>Targeting BCL-2 in MDS</td>
<td>Amer Zeidan, MBBS</td>
<td><a href="https://soho.click/mds3">https://soho.click/mds3</a> Yale Cancer Center New Haven, Connecticut, USA</td>
</tr>
<tr>
<td>2:25 PM</td>
<td>Targeting p53 in MDS</td>
<td>David Sallman, MD</td>
<td><a href="https://soho.click/mds4">https://soho.click/mds4</a> H. Lee Moffitt Cancer Center Tampa, Florida, USA</td>
</tr>
<tr>
<td>2:43 PM</td>
<td>IDH inhibitors in MDS</td>
<td>Courtney D. DiNardo, MD, MSCE</td>
<td><a href="https://soho.click/mds5">https://soho.click/mds5</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>3:01 PM</td>
<td><strong>Oral Abstract:</strong> MDS-254: SF3B1: Splicing Mutation in the Context of Therapy-Related MDS</td>
<td>Virginia Volpe, MD</td>
<td><a href="https://soho.click/mds6">https://soho.click/mds6</a> H. Lee Moffitt Cancer Center Tampa, Florida, USA</td>
</tr>
<tr>
<td>3:11 PM</td>
<td><strong>Exhibit Hall Experience</strong></td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
<tr>
<td><strong>SESSION III: ACUTE MYELOID LEUKEMIA</strong></td>
<td>Session Chairs: Richard Stone and Farhad Ravandi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:41 PM</td>
<td>State of the Art in AML</td>
<td>Laura C. Michaelis, MD</td>
<td><a href="https://soho.click/aml1">https://soho.click/aml1</a> Medical College of Wisconsin Milwaukee, Wisconsin, USA</td>
</tr>
<tr>
<td>3:59 PM</td>
<td>Germline Mutations in AML</td>
<td>Coleman Lindsley, MD, PhD</td>
<td><a href="https://soho.click/aml2">https://soho.click/aml2</a> Dana-Farber Cancer Institute Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>4:17 PM</td>
<td>Harnessing Apoptosis in AML</td>
<td>Marina Konopleva, MD, PhD</td>
<td><a href="https://soho.click/aml3">https://soho.click/aml3</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>4:35 PM</td>
<td>The Problem of Mutant P53 AML</td>
<td>David Sallman, MD</td>
<td><a href="https://soho.click/aml4">https://soho.click/aml4</a> H. Lee Moffitt Cancer Center Tampa, Florida, USA</td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:53 PM</td>
<td>Targeting CD123 in AML</td>
<td>Andrew A. Lane, MD, PhD</td>
<td><a href="https://soho.click/aml5">https://soho.click/aml5</a> Dana-Farber Cancer Institute Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>5:11 PM</td>
<td><strong>DEBATE</strong> Fit Older Adults Between 60-75 in First Remission on Either Extreme of the Prognostic Spectrum Should Undergo Allo SCT</td>
<td>Edwin Pascal Alyea, MD</td>
<td><a href="https://soho.click/aml6">https://soho.click/aml6</a> Duke University School of Medicine Durham, North Carolina, USA</td>
</tr>
<tr>
<td>5:26 PM</td>
<td>Not Undergo Allo SCT</td>
<td>Uma Borate, MD, MS</td>
<td><a href="https://soho.click/aml7">https://soho.click/aml7</a> Oregon Health &amp; Science University Portland, Oregon, USA</td>
</tr>
<tr>
<td>5:47 PM</td>
<td>Novel Antibodies in AML</td>
<td>Marion Subklewe, MD</td>
<td><a href="https://soho.click/aml8">https://soho.click/aml8</a> Ludwig-Maximilians-University of Munich Munich, Germany</td>
</tr>
<tr>
<td>6:05 PM</td>
<td>Oral Abstract</td>
<td>Courtney D. DiNardo, MD, MSCE</td>
<td><a href="https://soho.click/aml9">https://soho.click/aml9</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>6:15 PM</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**POSTER SESSION & WELCOME RECEPTION**

- **Poster Session and Awards**
  - [https://soho.click/posters](https://soho.click/posters)

**INDEPENDENT SATELLITE SYMPOSIUM I**

- **Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?**
  - [Coming Soon](https://tinyurl.com/RMESOHO20)
  - Jesus Berdeja, MD, Tennessee Oncology | Joshua Richter, MD, Mount Sinai

This CME activity is jointly provided by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. This activity is supported by educational grants from Amgen and Bristol-Myers Squibb, and Oncopeptides. Please visit [https://tinyurl.com/RMESOHO20](https://tinyurl.com/RMESOHO20) for more information on this program.

**Thursday, September 10, 2020**

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 AM</td>
<td>The Evolving Therapeutic Landscape in Relapsed Refractory Multiple Myeloma</td>
<td>Sagar Lonial, MD, FACP</td>
<td><a href="https://soho.click/iss2">https://soho.click/iss2</a> Emory University, Atlanta, USA – Chair Adam Cohen, MD</td>
</tr>
</tbody>
</table>

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*
## MEETING PROGRAM

### BREAKFAST WITH THE EXPERTS

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>CAR T for Myeloid Leukemias – Current Status</td>
<td>Elizabeth L. Budde, MD, PhD</td>
<td><a href="https://soho.click/eb1">https://soho.click/eb1</a> City of Hope National Medical Center Duarte, California, USA</td>
</tr>
<tr>
<td>7:45 AM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

### SESSION IV: MYELOPROLIFERATIVE NEOPLASMS

Session Chairs: Srdan Verstovsek and Laura Michaelis

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Genomics in Myelofibrosis: Practical Guidelines for Its Use in Clinical Practice</td>
<td>Raajit K. Rampal, MD, PhD</td>
<td><a href="https://soho.click/mpn1">https://soho.click/mpn1</a> Memorial Sloan Kettering Cancer Center New York, New York, USA</td>
</tr>
<tr>
<td>8:18 AM</td>
<td>New Therapies in Development for Myelofibrosis</td>
<td>Srdan Verstovsek, MD, PhD</td>
<td><a href="https://soho.click/mpn2">https://soho.click/mpn2</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>8:36 AM</td>
<td>Improved Outcomes with Transplant for MPN</td>
<td>Uday Popat, MD</td>
<td><a href="https://soho.click/mpn3">https://soho.click/mpn3</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>8:54 AM</td>
<td>CASE PRESENTATION: Thrombosis in PV: How to Predict and How to Reduce the Risk</td>
<td>Gabriela Hobbs, MD</td>
<td><a href="https://soho.click/mpn4">https://soho.click/mpn4</a> Massachusetts General Hospital Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>9:12 AM</td>
<td>CASE PRESENTATION: Post PV and Post ET MF: What A Doctor Needs to Know</td>
<td>Laura C. Michaelis, MD</td>
<td><a href="https://soho.click/mpn5">https://soho.click/mpn5</a> Medical College of Wisconsin Milwaukee, Wisconsin, USA</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Oral Abstract</td>
<td>MPN-188: Myeloablative Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors</td>
<td>Jacinth Joseph, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

### SESSION V: MULTIPLE MYELOMA

Session Chairs: Sagar Lonial and Thomas Martin

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 AM</td>
<td>Frontline Therapy for Frail Older Patients</td>
<td>Brea C. Lipe, MD</td>
<td><a href="https://soho.click/mm1">https://soho.click/mm1</a> The University of Rochester Rochester, New York, USA</td>
</tr>
<tr>
<td>10:28 AM</td>
<td>DEBATE: Frontline Therapy for Fit MM Should Include an Antibody</td>
<td>Peter M. Voorhees, MD</td>
<td><a href="https://soho.click/mm2">https://soho.click/mm2</a> Levine Cancer Institute Charlotte, North Carolina, USA</td>
</tr>
<tr>
<td>10:43 AM</td>
<td>Should NOT Include an Antibody</td>
<td>Thomas G. Martin, MD</td>
<td><a href="https://soho.click/mm3">https://soho.click/mm3</a> University of California San Francisco San Francisco, California, USA</td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).
### MEETING PROGRAM

#### (...cont. from p. 27)

**TIME (UTC-5)** | **TOPIC/SESSION** | **SPEAKER** | **VIRTUAL LINK/AFFILIATION**
--- | --- | --- | ---
**(...CONT) SESSION V: MULTIPLE MYELOMA** | | | |
11:04 AM | **DEBATE:** Smoldering MM Should Be Treated Early | Maria-Victoria Mateos, MD, PhD | [https://soho.click/mm4](https://soho.click/mm4) University Hospital of Salamanca Salamanca, Spain |
11:19 AM | Should NOT Be Treated Early | Angela Dispenzieri, MD | [https://soho.click/mm5](https://soho.click/mm5) Mayo Clinic Rochester Rochester, Minnesota, USA |
11:40 AM | Role of HDT in Current Treatment for MM | Ajay K. Nooka, MD, MPH, FACP | [https://soho.click/mm6](https://soho.click/mm6) Winship Cancer Institute Atlanta, Georgia, USA |
11:58 AM | Management of Early Relapse | Robert Z. Orlowski, MD, PhD | [https://soho.click/mm7](https://soho.click/mm7) MD Anderson Cancer Center Houston, Texas, USA |
12:16 PM | **Oral Abstract** | Ajay K. Nooka, MD, MPH, FACP | [https://soho.click/mm8](https://soho.click/mm8) Winship Cancer Institute Atlanta, Georgia, USA |
| MM-350: Subgroup Analysis of GRIFFIN in African American/Eligible Newly Diagnosed Multiple Myeloma (NDMM) | | | |
INDUSTRY EXPERT LUNCH SESSION IIA* | | | |
12:26 PM | IMMUNO-ONCOLOGY AND MDS: Current Knowledge and Future Perspectives | Naval Daver, MD | [https://soho.click/ies2a](https://soho.click/ies2a) MD Anderson Cancer Center Houston, Texas, USA |
| | | Guillermo Garcia-Manero, MD | MD Anderson Cancer Center Houston, Texas, USA |
| | | This activity is supported by Novartis | | |
INDUSTRY EXPERT LUNCH SESSION IIB* | | | |
12:26 PM | Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea | David Rizzieri, MD | [https://soho.click/ies2b](https://soho.click/ies2b) Duke University School of Medicine Durham, North Carolina, USA |
| | | This activity is supported by Incyte | | |
1:26 PM | **Exhibit Hall Experience** | | [https://soho.click/exhibits](https://soho.click/exhibits) |
PLENARY SESSION II | | | |
Session Chair: Sagar Lonial | | | |
1:56 PM | BCMA Directed Therapy for MM | Nikhil C. Munshi, MD | [https://soho.click/plen2](https://soho.click/plen2) Dana-Farber Cancer Institute Boston, Massachusetts, USA |

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*

(...continued on p. 29)
MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION VI: CHRONIC LYMPHOCYTIC LEUKEMIA</strong>&lt;br&gt;Session Chairs: Jennifer Brown and Florence Cymbalista</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:16 PM</td>
<td>Next Generation of BCR Inhibitors</td>
<td>Paolo Ghia, MD, PhD</td>
<td><a href="https://soho.click/cll1">https://soho.click/cll1</a> Università Vita-Salute San Raffaele Milano, Italy</td>
</tr>
<tr>
<td>2:34 PM</td>
<td>Measuring Residual Disease, Clinical Implications</td>
<td>William Wierda, MD, PhD</td>
<td><a href="https://soho.click/cll2">https://soho.click/cll2</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>2:52 PM</td>
<td>What Is Fitness in the Era of Targeted Agents</td>
<td>Alessandra Tedeschi, MD</td>
<td><a href="https://soho.click/cll3">https://soho.click/cll3</a> Niguarda Cancer Center Niguarda, Milan, Italy</td>
</tr>
<tr>
<td>3:10 PM</td>
<td><strong>DEBATE:</strong> is the Best Frontline Option for CLL&lt;br&gt;<strong>BTK Inhibitor</strong></td>
<td>John C. Byrd, MD</td>
<td><a href="https://soho.click/cll4">https://soho.click/cll4</a> The Ohio State University Columbus, Ohio, USA</td>
</tr>
<tr>
<td>3:25 PM</td>
<td><strong>BCL2 Inhibitor</strong></td>
<td>Michael Hallek, MD</td>
<td><a href="https://soho.click/cll5">https://soho.click/cll5</a> University Hospital of Cologne Cologne, Germany</td>
</tr>
<tr>
<td>3:46 PM</td>
<td>Cellular Therapies in CLL</td>
<td>Elizabeth J. Shpall, MD</td>
<td><a href="https://soho.click/cll6">https://soho.click/cll6</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>4:04 PM</td>
<td><strong>Oral Abstract</strong></td>
<td>Paolo Ghia, MD, PhD</td>
<td><a href="https://soho.click/cll7">https://soho.click/cll7</a> Università Vita-Salute San Raffaele Milano, Italy</td>
</tr>
<tr>
<td>4:14 PM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
<tr>
<td>4:44 PM</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDUSTRY EXPERT SESSION III**<br>This activity is supported by Pfizer

| 4:44 PM | A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy | Jorge Cortés, MD | [https://soho.click/ies3](https://soho.click/ies3) Georgia Cancer Center Augusta, Georgia, USA |

**INDUSTRY EXPERT SESSION IV**<br>This activity is supported by Jazz Pharmaceuticals Inc.

| 5:44 PM | A Case-based Discussion on Improving Outcomes in Patients with Newly Diagnosed Secondary AML | Usama Gergis, MD, MBA | [https://soho.click/ies4](https://soho.click/ies4) Weill Cornell Medical College New York, New York, USA |

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDEPENDENT SATELLITE SYMPOSIUM III</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 6:44 PM | Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios | Prithviraj Bose, MD - Chair | Ruben Mesa, MD | Raajit K. Rampal, MD, PhD  
This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb, and Incyte. | https://soho.click/iss3 |

**Friday, September 11, 2020**

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDEPENDENT SATELLITE SYMPOSIUM IV</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 6:30 AM | Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum | William G. Wierda, MD, PhD | Philip A. Thompson, MB, MS | The University of Texas MD Anderson Cancer Center  
This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education  
This activity is supported by an independent educational grant from AstraZeneca  
For more information and to register for the live ISS, go to PeerView.com/CLL20Live | https://soho.click/iss4 |

**BREAKFAST WITH THE EXPERT II**

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
</table>
| 6:45 AM | How to Move Beyond RCHOP | Sandeep S. Dave, MD, MS | Duke University School of Medicine  
Durham, North Carolina, USA | https://soho.click/eb2 |

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 AM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SESSION VII: HODGKIN LYMPHOMA**

Session Chairs: David Straus

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
</table>
| 8:00 AM | Newly Diagnosed HL | David J. Straus, MD | https://soho.click/hl1  
Memorial Sloan Kettering Cancer Center  
New York, New York, USA | |

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
</table>
| 8:18 AM | Relapsed HL | Alex F. Herrera, MD | https://soho.click/hl2  
City of Hope  
Duarte, California, USA | |

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
</table>
| 8:36 AM | Oral Abstract | Juan José Del Moral, MD | https://soho.click/hl3  
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán | |

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*
### MEETING PROGRAM

(...cont. from p. 30)

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION VIII: T-CELL LYMPHOMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Session Chairs: Steven Horwitz and Francisco Vega</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:46 AM Pathology and Pathogenesis of T Cell Lymphoma</td>
<td>Francisco Vega, MD PhD</td>
<td><a href="https://soho.click/tcl1">https://soho.click/tcl1</a> MD Anderson Cancer Center Houston, Texas, USA</td>
<td></td>
</tr>
<tr>
<td>9:04 AM Newly Diagnosed</td>
<td>Keny Savage, MD</td>
<td><a href="https://soho.click/tcl2">https://soho.click/tcl2</a> BC Cancer Vancouver, Canada</td>
<td></td>
</tr>
<tr>
<td>9:22 AM Relapsed TCell Lymphoma</td>
<td>Steven M. Horwitz, MD</td>
<td><a href="https://soho.click/tcl3">https://soho.click/tcl3</a> Memorial Sloan Kettering Cancer Center New York, New York, USA</td>
<td></td>
</tr>
<tr>
<td>9:50 AM <strong>Exhibit Hall Experience</strong></td>
<td></td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

| **SESSION IX: INDOLENT B-CELL LYMPHOMA** | | | |
| Session Chairs: Nathan Fowler | | | |
| 10:20 AM Management of Newly Diagnosed FL | Nathan H. Fowler, MD | [https://soho.click/ibcl1](https://soho.click/ibcl1) MD Anderson Cancer Center Houston, Texas, USA |
| 10:38 AM Relapsed FL | Nathan H. Fowler, MD | [https://soho.click/ibcl2](https://soho.click/ibcl2) MD Anderson Cancer Center Houston, Texas, USA |
| 10:56 AM Marginal Zone Lymphoma | Emanuele Zucca, MD | [https://soho.click/ibcl3](https://soho.click/ibcl3) Oncology Institute of Southern Switzerland Bellinzona, Switzerland |
| 11:14 AM Waldenstrom | Morie A. Gertz, MD | [https://soho.click/ibcl4](https://soho.click/ibcl4) Mayo Clinic Rochester, Minnesota, USA |
| 11:32 AM **Oral Abstract** IBCL-344: Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center | Rosana Córdova, MD | [https://soho.click/ibcl5](https://soho.click/ibcl5) Instituto Nacional de Cancerología Mexico City, Mexico |

| **INDUSTRY EXPERT LUNCH SESSION VA** | | | |
| 11:42 AM Redefining Approaches in Frontline Chronic Lymphocytic Leukemia (CLL) Treatment Imbruvica® +Rituximab vs FCR: Head-to-Head- Data in Frontline CLL/SLL | Nakhir Saba, MD | [https://soho.click/ies5a](https://soho.click/ies5a) Tulane University New Orleans, Louisiana, USA Hematology Oncology of Indiana Indianapolis, Indiana |

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*
MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:42 AM</td>
<td><strong>Explore Yescarta @: CAR TTherapy, for Patients in Your Practice</strong></td>
<td>John Pagel, MD, PhD</td>
<td><a href="https://soho.click/ies5b">https://soho.click/ies5b</a></td>
</tr>
<tr>
<td></td>
<td>This activity is supported by Kite Pharma</td>
<td></td>
<td>Swedish Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Seattle, Washington, USA</td>
</tr>
<tr>
<td>12:42 PM</td>
<td><strong>Exhibit Hall Experience</strong></td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

PLENARY SESSION III

Session Chair: Hagop Kantarjian

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:12 PM</td>
<td><strong>My Take on Prognostication and Management of Essential Thrombocythemia</strong></td>
<td>Ayalew Tefferi, MD</td>
<td><a href="https://soho.click/plen3">https://soho.click/plen3</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mayo Clinic Rochester</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rochester Minnesota, USA</td>
</tr>
</tbody>
</table>

SESSION X: AGGRESSIVE B-CELL LYMPHOMA

Session Chairs: Martin Hutchings and Sonali Smith

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:32 PM</td>
<td><strong>Novel Immunotherapeutic Agents in Aggressive B-NHL</strong></td>
<td>Martin Hutchings, MD, PhD</td>
<td><a href="https://soho.click/abc11">https://soho.click/abc11</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Copenhagen University Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>1:50 PM</td>
<td><strong>Relapsed DLBCL</strong></td>
<td>Sonali M. Smith, MD, FASCO</td>
<td><a href="https://soho.click/abc12">https://soho.click/abc12</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The University of Chicago</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chicago, Illinois, USA</td>
</tr>
<tr>
<td>2:08 PM</td>
<td><strong>CAR TCells</strong></td>
<td>Peter Riedell, MD</td>
<td><a href="https://soho.click/abc13">https://soho.click/abc13</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chicago, Illinois, USA</td>
</tr>
<tr>
<td>2:26 PM</td>
<td><strong>Oral Abstract</strong></td>
<td>ABCL-256: Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma: A Real-World Study</td>
<td>Shengling Ma, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Union Hospital, Tongji Medical College</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wuhan, China</td>
</tr>
<tr>
<td>2:36 PM</td>
<td><strong>Exhibit Hall Experience</strong></td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

SESSION XI: MANTLE CELL LYMPHOMA

Session Chairs: Robert Marcus

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:06 PM</td>
<td><strong>Frontline Treatment of Mantle Cell Lymphoma</strong></td>
<td>Steven Le Gouill, MD, PhD</td>
<td><a href="https://soho.click/mcl1">https://soho.click/mcl1</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nantes University Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nantes, France</td>
</tr>
<tr>
<td>3:24 PM</td>
<td><strong>Relapsed MCL</strong></td>
<td>Jonathon B. CohenMD, MS</td>
<td><a href="https://soho.click/mcl2">https://soho.click/mcl2</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Winship Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Atlanta, Georgia, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Houston, Texas, USA</td>
</tr>
</tbody>
</table>

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting

(...continued on p. 31)
MEETING PROGRAM

SESSION XII: CELLULAR THERAPY

Session Chairs: Renier Brentjens and Sergio Giralt

3:52 PM Adding Vaccines to the Immunotherapy Cocktail
David E. Avigan, MD
Beth Israel Deaconess Medical Center
Boston, Massachusetts, USA
https://soho.click/ct1

4:10 PM New CAR Designs
Renier J. Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York, USA
https://soho.click/ct2

4:28 PM Optimizing Lymphodepletion Prior to CAR T Cell Therapy
Elizabeth L. Budde, MD, PhD
City of Hope National Medical Center
Duarte, California, USA
https://soho.click/ct3

4:46 PM Oral Abstract | CT-279: Story of Success of Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis of Clinical Outcome
Ghada ELGohary, MD
Ain Shams University
Cairo, Egypt
https://soho.click/ct4

4:56 PM Adjourn

INDUSTRY EXPERT SESSION VI*

4:56 PM XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients
Naval Daver, MD
MD Anderson Cancer Center
Houston, Texas, USA
https://soho.click/ies6

This activity is supported by Astellas

INDEPENDENT SATELLITE SYMPOSIUM V*

5:56 PM The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-based Treatment From CD38 to BCMA
Sagar Lonial, MD, FACP | Robert Z. Orlowski, MD, PhD
This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from GlaxoSmithKline. For more information and to register for the live ISS, go to PeerView.com/MM20-Live
https://soho.click/iss5

INDEPENDENT SATELLITE SYMPOSIUM VI*

6:56 PM Treating Multiple Myeloma in 2020 - Best Approaches to Optimizing Patient Outcomes
Robert Z. Orlowski, MD, PhD - Chair | María-Victoria Mateos, MD, PhD | Paul Richardson, MD
This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend. This activity is supported by an educational grant from GlaxoSmithKline and Oncoproteins. For more information and to register for this ISS, go to www.BioAscend.com/SOHOMM.
https://soho.click/iss6

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting

(...continued on p. 34)
**MEETING PROGRAM**

**Saturday, September 12, 2020**

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDUSTRY EXPERT SESSION VII</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:45 AM</td>
<td>Discover the Role of Two Immunotherapies in Myeloma Treatment</td>
<td>Melhem M. Solh, MD</td>
<td><a href="https://soho.click/ies7">https://soho.click/ies7</a> Northside Hospital Atlanta, Georgia, USA</td>
</tr>
<tr>
<td></td>
<td>This activity is supported by Bristol-Myers Squibb</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BREAKFAST WITH THE EXPERT III**

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>CML Update</td>
<td>Michael Deininger, MD, PhD</td>
<td><a href="https://soho.click/eb3">https://soho.click/eb3</a> Huntsman Cancer Hospital Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td>7:45 AM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

**SESSION XIII: CHRONIC MYELOID LEUKEMIA**

**Session Chairs: Simona Soverini**

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>CML: State of the Art Update</td>
<td>Delphine Rea, MD, PhD</td>
<td><a href="https://soho.click/cml1">https://soho.click/cml1</a> Hôpital Saint Louis Paris, France</td>
</tr>
<tr>
<td>8:18 AM</td>
<td>New Therapeutic Options in CML</td>
<td>Jorge Cortés, MD</td>
<td><a href="https://soho.click/cml2">https://soho.click/cml2</a> Georgia Cancer Center Augusta, Georgia, USA</td>
</tr>
<tr>
<td>8:36 AM</td>
<td>Update on CML-Like Disorders</td>
<td>Nick Cross, MA, PhD, FRCPath</td>
<td><a href="https://soho.click/cml3">https://soho.click/cml3</a> University of Southampton Salisbury, United Kingdom</td>
</tr>
<tr>
<td>8:54 AM</td>
<td><strong>Case Studies: The Challenges of TFR</strong></td>
<td>Timothy P. Hughes, MD, FRACP, FRCPA</td>
<td><a href="https://soho.click/cml4">https://soho.click/cml4</a> South Australian Health and Medical Research Institute, Adelaide, Australia</td>
</tr>
<tr>
<td>9:12 AM</td>
<td>The Molecular Complexity of CML</td>
<td>Jerald P. Radich, MD</td>
<td><a href="https://soho.click/cml5">https://soho.click/cml5</a> Fred Hutchinson Cancer Research Center Seattle, Washington, USA</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Exhibit Hall Experience</td>
<td></td>
<td><a href="https://soho.click/exhibits">https://soho.click/exhibits</a></td>
</tr>
</tbody>
</table>

**SESSION XIV: NEXT QUESTIONS**

**Session Chairs: Sagar Lonial and Selina Luger**

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 AM</td>
<td>Next Questions: Acute Lymphoblastic Leukemia</td>
<td>Selina M. Luger, MD</td>
<td><a href="https://soho.click/nq1">https://soho.click/nq1</a> Abramson Cancer Center Philadelphia, Pennsylvania, USA</td>
</tr>
</tbody>
</table>

*Independent Sessions are not part of the official educational program of the Society of Hematologic Oncology Annual Meeting*
### MEETING PROGRAM

<table>
<thead>
<tr>
<th>TIME (UTC-5)</th>
<th>TOPIC/SESSION</th>
<th>SPEAKER</th>
<th>VIRTUAL LINK/AFFILIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION XIV: NEXT QUESTIONS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 AM</td>
<td>Next Questions: Acute Myeloid Leukemia</td>
<td>Amer Zeidan, MBBS</td>
<td><a href="https://soho.click/nq2">https://soho.click/nq2</a> Yale Cancer Center New Haven, Connecticut, USA</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Next Questions: Cellular Therapy</td>
<td>Sergio Giralt, MD</td>
<td><a href="https://soho.click/nq3">https://soho.click/nq3</a> Memorial Sloan Kettering Cancer Center New York, New York, USA</td>
</tr>
<tr>
<td>10:40 AM</td>
<td>Next Questions: Myelodysplastic Leukemia</td>
<td>Guillermo Garcia-Manero, MD</td>
<td><a href="https://soho.click/nq12">https://soho.click/nq12</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Next Questions: Chronic Myeloid Syndromes</td>
<td>Michael Deininger, MD, PhD</td>
<td><a href="https://soho.click/nq5">https://soho.click/nq5</a> Huntsman Cancer Hospital Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Next Questions: Aggressive B-Cell Lymphoma</td>
<td>Sandeep S. Dave, MD, MS</td>
<td><a href="https://soho.click/nq6">https://soho.click/nq6</a> Duke University School of Medicine Durham, North Carolina, USA</td>
</tr>
<tr>
<td>11:10 AM</td>
<td>Next Questions: Indolent B-Cell Lymphoma</td>
<td>Robert Marcus, MA, FRCP, FRCPath</td>
<td><a href="https://soho.click/nq7">https://soho.click/nq7</a> Leaders in Oncology Care London, United Kingdom</td>
</tr>
<tr>
<td>11:20 AM</td>
<td>Next Questions: T-Cell Lymphoma</td>
<td>Kenny Savage, MD</td>
<td><a href="https://soho.click/nq8">https://soho.click/nq8</a> BC Cancer Vancouver, Canada</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Next Questions: Mantle Cell Lymphoma</td>
<td>Jonathon B. Cohen, MD, MS</td>
<td><a href="https://soho.click/nq9">https://soho.click/nq9</a> Winship Cancer Institute Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>Next Questions: Hodgkin Lymphoma</td>
<td>David J. Straus, MD</td>
<td><a href="https://soho.click/nq10">https://soho.click/nq10</a> Memorial Sloan Kettering Cancer Center New York, New York, USA</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Next Questions: Multiple Myeloma</td>
<td>Sagar Lonial, MD, FACP</td>
<td><a href="https://soho.click/nq11">https://soho.click/nq11</a> Winship Cancer Institute Atlanta, Georgia, USA</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Next Questions: Chronic Lymphocytic Leukemia</td>
<td>Jennifer R. Brown, MD, PhD</td>
<td><a href="https://soho.click/nq4">https://soho.click/nq4</a> Dana-Farber Cancer Institute Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Next Questions: Myeloproliferative Neoplasms</td>
<td>Prithviraj Bose, MD</td>
<td><a href="https://soho.click/nq13">https://soho.click/nq13</a> MD Anderson Cancer Center Houston, Texas, USA</td>
</tr>
<tr>
<td>12:20 PM</td>
<td>Closing Remarks</td>
<td>Sagar Lonial, MD, FACP</td>
<td><a href="https://soho.click/close">https://soho.click/close</a></td>
</tr>
<tr>
<td>12:35 PM</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All times are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC/GMT -5).
PROGRAM FACULTY

Meeting Chairpersons
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA, USA

Hagop Kantarjian, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Emil J Freireich, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Invited Faculty
Edwin Pascal Alyea, MD
Duke University School of Medicine
Durham, NC, USA

David E. Avigan, MD
Beth Israel Deaconess Medical Center
Boston, MA, USA

Uma Borate, MD, MS
Oregon Health & Science University
Portland, OR, USA

Prithviraj Bose, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Renier J. Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Jennifer R. Brown, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, USA

Elizabeth Budde, MD, PhD
City of Hope National Medical Center
Duarte, CA, USA

John C. Byrd, MD
The Ohio State University
Comprehensive Cancer Center
Columbus, OH, USA

Sabina Chiaretti, MD, PhD
La Sapienza University
Rome, Italy

Jonathon B. Cohen, MD, MS
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA, USA

Rosana Córdova, MD
Instituto Nacional de Cancerología
Mexico City, Mexico

Jorge Cortés, MD
Georgia Cancer Center at Augusta University
Augusta, GA, USA

Nick Cross, MA, PhD, FRCPath
University of Southampton
Salisbury, UK

Emily K. Curran, MD
The University of Cincinnati
Cincinnati, OH, USA

Florence Cymbalista, MD, PhD
Hôpital Avicenne
Bobigny, France

Sandep S. Dave, MD, MS
Duke University School of Medicine
Durham, NC, USA

Stéphane De Botton, MD
Institut de Cancérologie Gustave Roussy
Villejuif, France

Marcos de Lima, MD
UH Cleveland Medical Center
Cleveland, OH, USA

Michael W. Deininger, MD, PhD
University of Utah
Huntsman Cancer Institute
Salt Lake City, UT, USA

Juan José Del Moral, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico

Courtney D. Dinardo, MD, MSCE
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

John DiPersio, MD, PhD
Washington University School of Medicine
St. Louis, MO, USA

Angela Dispenzieri, MD
Mayo Clinic Rochester
Rochester, MN, USA

Eldadah Saleem, MD
Princess Noorah Oncology Center
Jeddah, Saudi Arabia

Ghada EGohary, MD
Ain Shams University
Cairo, Egypt

Alessandra Ferrajoli, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Christopher R Flowers, MD, MS
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Nathan H. Fowler, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

(...continued on p. 37)
Guillermo García-Manero, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Morie A. Gertz, MD, MACP
Mayo Clinic
Rochester, MN, USA

Larisa Geskin, MD
New York Presbyterian Hospital
New York, NY, USA

Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
Milano, Italy

Sergio Giralt, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Michael Hallek, MD
University Hospital of Cologne
Cologne, Germany

Alex F. Hemra, MD
City of Hope National Medical Center
Duarte, CA, USA

Jens Hillengass, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY, USA

Gabriela Hobbs, MD
Massachusetts General Hospital
Boston, MA, USA

Steven M. Horwitz, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Timothy P. Hughes, MD, FRACP, FRCPA
South Australian Health and Medical Research Institute
Adelaide, Australia

Martin Hutchings, MD, PhD
National Hospital Copenhagen
Copenhagen, Denmark

Elias Jabbour, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Nitin Jain, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Andrzej Jakubowiak, MD, PhD
University of Chicago Medicine
Chicago, IL, USA

Joseph Jacinth, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Rami S. Komrokji, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA

Maria Y. Konopleva, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Andrew A. Lane, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, USA

Steven Le Gouill, MD, PhD
Nantes University Hospital
Nantes, France

Suzanne Lenzsch, MD, PhD
Columbia University and at New York Presbyterian Hospital
New York, NY, USA

Coleman Lindsley, MD, PhD
Dana-Farber Cancer Institute
Boston, MA, USA

Brea C. Lipe, MD
The University of Rochester
Rochester, NY, USA

Aaron Logan, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA, USA

Selina M. Luger, MD
University of Pennsylvania
Abramson Cancer Center
Philadelphia, PA, USA

Marise R. Luskin, MD, MSCE
Dana Farber Cancer Institute
Boston, MA, USA

Shengling Ma, MD
Huazhong University of Science
Wuhan, China

Robert Marcus, MA, FRCP, FRCPath
Leaders in Oncology Care
London, UK

Thomas G. Martin, MD
University of California San Francisco
San Francisco, CA, USA

Maria-Victoria Mateos, MD, PhD
University Hospital of Salamanca
Salamanca, Spain

Richard T. Maziarz, MD
Knight Cancer Institute
Portland, OR, USA

Jennifer McNeer, MD, MS
The University of Chicago Medicine
Chicago, IL, USA

(...continued on p. 38)
PROGRAM FACULTY

John Seymour, MBBS, FRACP, PhD
Peter MacCallum Cancer Centre &
The Royal Melbourne Hospital
Melbourne, Australia

Nicholas J. Short, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Elizabeth J. Shpall, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Catherine Smith, MD
University of California San Francisco
San Francisco, CA, USA

Sonali M. Smith, MD, FASCO
The University of Chicago
Chicago, IL, USA

Simona Soverini, PhD
University of Bologna
Bologna, Italy

David J. Straus, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Marion Subklewe, MD
Ludwig-Maximilians-University of Munich
Munich, Germany

Koichi Takahashi, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Alessandra Tedeschi, MD
Niguarda Cancer Center
Milan, Italy

Ayalew Tefferi, MD
Mayo Clinic Rochester
Rochester, MN, USA

Sheeba K. Thomas, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Philip A. Thompson, MB, BS
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Geoffrey L. Uy, MD
Washington University School of Medicine
St. Louis, MO, USA

Francisco Vega, MD PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Srdan Verstovsek, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Virginia Volpe, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL, USA

Peter M. Voorhees, MD
Levine Cancer Institute
Charlotte, NC, USA

Vitae Paresh Vyas, MRCPath, FRCP,
FRCPath
University of Oxford
Oxford, UK

Michael L. Wang, MD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

William G. Wierda, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX, USA

Joachim Yahalom, MD, FACR
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Jun J. Yang, PhD
St. Jude Children's Research Hospital
Memphis, TN, USA

Amer Zeidan, MBBS
Yale Cancer Center
New Haven, CT, USA

Pier Luigi Zinzani, MD, PhD
University of Bologna
Bologna, Italy

Emanuele Zucca, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
VIRTUAL EVENT VENUE
The eighth annual meeting of the Society of Hematologic Oncology is being held as a virtual event. Once registered, you may enter the virtual environment through the SOHO 2020 lobby at https://soho.click/lobby or at https://soho.6connex.com/event/AnnualMeeting/login/.

REGISTRATION AND GENERAL INFORMATION
Registration is located at https://www.soho2020.com/. You may login to check your registration and session selections. Note that you do not need to register for a specific session in order to participate on the virtual platform.

Direct links to sessions are included in the program listing. In addition, you may enter the virtual environment through the SOHO 2020 lobby at https://soho.click/lobby or at https://soho.6connex.com/event/AnnualMeeting/login/.

RESOURCES
The SOHO 2020 Resource Center is located at https://soho.click/resources. The Resource Center provides attendees with direct links and downloads of the official SOHO 2020 program, the SOHO 2020 Abstract Proceedings, Speakers’ Slides, E-Poster viewing, the SOHO Daily News series and much more.

HELP DESK
If you have questions or technical difficulties, do not hesitate to contact us at the “Help Desk” located in the virtual environment at https://soho.click/help. You may also email Melinda White at mwhite@jwccinc.com.

EXHIBITION
We would like to thank our supporting companies who have joined us with a virtual exhibition booth, and ask you to please support them by visiting their exhibit during your time on on the virtual platform.

Remember to visit as many exhibitors as possible. The more times that you visit booths, download content or view videos, the more points you earn. The three individuals with the greatest number of points will win one of three prizes.

Watch the ‘Leaderboard’ to see if you are one of the lucky winners!

First Prize: Apple Watch 5/GPS/Cellular
Second Prize: $500 Amazon Gift Card
Third Place: $250 Amazon Gift Card

Winners will be announced at the conclusion of the annual meeting on September 9, 2020.

INDUSTRY EXPERT SESSIONS
There are 10 Industry Expert Session presentations scheduled at the following times. For more information, go to page 42 for session details. Viewing of sessions is available in the General Session Auditorium at https://soho.click/gs.

Wednesday, September 9
11:41 am – 12:41 pm
Wednesday, September 9
11:41 am – 12:41 pm
Thursday, September 10
12:26 pm – 1:26 pm
Thursday, September 10
12:26 pm – 1:26 pm
Thursday, September 10
4:44 pm – 5:44 pm
Thursday, September 10
5:44 pm – 6:44 pm
Friday, September 11
11:42 pm – 12:42 pm
Friday, September 11
11:42 pm – 12:42 pm
Friday, September 11
4:56 pm – 5:56 pm
Saturday, September 12
6:45 am – 7:45 am

Wednesday, September 9
8:15 pm – 9:45 pm
Thursday, September 10
6:15 am – 7:45 am
Thursday, September 10
6:44 pm – 8:14 am
Friday, September 11
6:30 am – 7:45 am
Friday, September 11
5:56 pm – 6:56 pm
Friday, September 11
6:56 pm – 8:26 pm

INDEPENDENT SATELLITE SYMPOSIA
There are 6 Independent Satellite Symposia (ISS) scheduled at the following times. For more information, go to page 41 for session details. Viewing of sessions is available in the General Session Auditorium at https://soho.click/gs.
The following Independent Satellite Symposia (ISS) activities and Industry Expert Sessions (IES) are not part of the official educational program of the Society of Hematologic Oncology’s eighth annual meeting and are not sponsored by SOHO, The University of Texas MD Anderson Cancer Center or the Louisiana State Nurses Association.

**INDEPENDENT SATELLITE SYMPOSIA**

**Wednesday, September 9, 2020**
8:15 PM-9:45 PM

*Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?*

**Jesus Berdeja, MD, Joshua Richter, MD**

This CME activity is jointly provided by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. This activity is supported by educational grants from Amgen and Bristol-Myers Squibb, and Oncopeptides.

Please visit [https://tinyurl.com/RME-SOHO20](https://tinyurl.com/RME-SOHO20) for more information on this program.

**Thursday, September 10, 2020**
6:15 AM-7:45 AM

*The Evolving Therapeutic Landscape in Relapsed Refractory Multiple Myeloma*

**Sagar Lonial, MD, FACP, Chair**

Adam Cohen, MD, Shaji Kumar, MD

This activity is supported by GlaxoSmithKline.

**Thursday, September 12, 2019**
6:44 PM-8:14 PM

*Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios*

**Prithviraj Bose, MD, Chair**

Ruben Mesa, MD, Raajit K. Rampal, MD, PhD

This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb, and Incyte.

**Friday, September 11, 2020**
6:30 AM-7:45 PM

*Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum*

**William G. Wierda, MD, PhD**

Philip A. Thompson, MB, MS

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from AstraZeneca.

For more information and to register for the live ISS, go to [PeerView.com/CLL20Live](http://PeerView.com/CLL20Live)

**Friday, September 11, 2020**
5:56 PM-6:56 PM

*The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-based Treatment From CD38 to BCMA*

**Sagar Lonial, MD, FACP**

Robert Z. Orlowski, MD, PhD

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from GlaxoSmithKline.

For more information and to register for the live ISS, go to [PeerView.com/MM20-Live](http://PeerView.com/MM20-Live)

**Friday, September 11, 2020**
6:56 PM-8:26 PM

*Treating Multiple Myeloma in 2020 - Best Approaches to Optimizing Patient Outcomes*

**Robert Z. Orlowski, MD, PhD, Chair**

Maria-Victoria Mateos, MD, PhD

Paul Richardson, MD

This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and BioAscend. This activity is supported by an educational grant from GlaxoSmithKline and Oncopeptides.

### INDUSTRY EXPERT SESSIONS

**Wednesday, September 9, 2020**
11:41 AM-12:41 PM

**An Acute Myeloid Leukemia Treatment Option for Patients**
Hetty Carraway, MD, MBA
This activity is supported by Bristol-Myers Squibb.

**Wednesday, September 9, 2020**
11:41 AM-12:41 PM

**A CAR T-cell Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma TECARIUS™ (brexucabtagenezaucel) Prescribing Information**
David Rizzieri, MD
This activity is supported by Kite Pharma.

**Thursday, September 10, 2020**
12:26 PM-1:26 PM

**IMMUNO-ONCOLOGY AND MDS: Current Knowledge and Future Perspectives**
Naval Daver, MD
Guillemo Garcia-Manero, MD
This activity is supported by Novartis

**Thursday, September 10, 2020**
12:26 PM-1:26 PM

**Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion. Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea.**
David Rizzieri, MD
This activity is supported by Incyte

**Thursday, September 10, 2020**
4:44 PM-5:44 PM

**A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy**
Jorge Cortes, MD
This activity is supported by Pfizer

**Thursday, September 10, 2020**
5:44 PM-6:44 PM

**A Case-based Discussion on Improving Outcomes in Patients With Newly-Diagnosed secondary AML**
Usama Gergis, MD, MBA
This activity is supported by Jazz Pharmaceuticals Inc.

**Friday, September 11, 2020**
11:42 AM-12:42 PM

**Redefining Approaches in Frontline Chronic Lymphocytic Leukemia (CLL) Treatment Imbruvica® + Rituximab vs FCR: Head-to-Head Data in Frontline CLL/SLL**
Nakhle Saba, MD, Tuemu Birhiray, MD
This activity is supported by Janssen Biotech & Pharmacyclics, LLC

**Friday, September 11, 2020**
4:56 PM-5:56 PM

**XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients**
Naval Daver, MD
This activity is supported by Astellas

**Saturday, September 12, 2020**
6:45 AM-7:45 AM

**Discover the Role of Two Immuno-therapies in Myeloma Treatment**
Melhem Solh, MD
This activity is supported by Bristol-Myers Squibb
INDEPENDENT SESSIONS

ON DEMAND INDEPENDENT SATELLITE SYMPOSIA

Managing AML: Staying on Track in a Rapidly Changing Treatment Landscape
Naval Daver, MD, Courtney DiNardo, MD, Eunice Wang, MD
This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb, Jazz Pharmaceuticals and Actinium.
https://soho.click/ISS7

Targeting Treatment in Relapsed/Refractory Multiple Myeloma: Experts Discuss Novel Agents, Combinations, and Ongoing Trials
Sagar Lonial, MD, FACP, Chair
Nina Shah, MD, Nikhil Munshi, MD
This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from GlaxoSmithKline and Oncopeptides, Inc.
https://soho.click/ISS8

New Horizons in the Management of Myelodysplastic Syndromes: Exploring Advancements from Low- to High-Risk Disease
Guillermo Garcia-Manero, MD, Chair
David Steensma, MD, Amy DeZern, MD
This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Agios Pharmaceuticals, Inc, Astex Pharmaceuticals, Inc, Bristol-Myers Squibb, and Takeda Oncology.
https://soho.click/ISS9

Illustrated Case Discussions: How Will You Leverage Recent Evidence in Relapsed/Refractory DLBCL Settings?
Christopher R. Flowers, M.D., M.S, Chair
Kami Maddocks, MD, Loretta J. Nastoupil, MD, Jason Westin, MD, MS, FACP, Oreofe O. Odejide, MD, MPH
This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from MorphoSys US, Inc.
https://soho.click/ISS10

(...cont. from p. 42)
You are invited to attend a virtual Independent Satellite Symposium (ISS) on multiple myeloma preceding the Society of Hematologic Oncology 2020 Annual Meeting.

Relapsed/Refractory

MULTIPLE MYELOMA:
What’s Next for Patients?

WEDNESDAY, SEPTEMBER 9, 2020
https://soho.6connex.com/event/annualmeeting/
8:15 PM – 9:45 PM CT  Virtual ISS

This CME-certified symposium will help oncology health care providers keep current on the newest investigational myeloma therapies for patients who are refractory to or have relapsed after multiple therapies.

There is no fee for attending this symposium. To preregister, please complete the form at https://tinyurl.com/RMESH020.

Join the discussion on Twitter: #RMELiveMM

NOTE: This symposium is available only to SOHO 2020 Annual Meeting attendees, to register for SOHO 2020, visit https://www.soho2020.com/.

Jointly provided by
MULTIPLE MYELOMA Research Foundation
PURDUE UNIVERSITY  RedMedEd

Supported by educational grants from Amgen, Inc., Bristol-Myers Squibb, and Oncopeptides.

SOHO 2020 VIRTUAL ENVIRONMENT

GENERAL SESSIONS
https://soho.click/gs

MEET THE PROFESSOR
https://soho.click/mtp

POSTER SESSION
https://soho.click/posters

RESOURCE CENTER
https://soho.click/resources

EXHIBIT HALL
https://soho.click/exhibits

NETWORKING LOUNGE
https://soho.click/lounge

https://soho.click/lobby
IMMERSE YOURSELF IN THE CALQUENCE DATA

[Please visit the CALQUENCE booth]